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ABSTRACT 
 
 
 Atg8 and its eukaryotic orthologues LC3 and GARBARAP family proteins 
(referred here to Atg8 family proteins) play crucial roles in autophagy through their 
covalent ligation to lipids, typically phosphatidylethanolamine (PE), in a process known 
as lipidation. Lipidation of Atg8 family proteins regulates numerous facets of the 
autophagy process, including regulating expansion of the phagophore membrane, 
recruiting selected cargoes for degradation, and providing an autophagosome membrane-
bound platform mediating dynamic interactions with other regulatory proteins. Atg8 
family proteins are ubiquitin-like proteins (UBLs), and their lipidation involves a 
divergent UBL conjugation cascade including Atg7, Atg3, and Atg12–Atg5-Atg16 acting 
as E1, E2, and E3 enzymes, respectively. Atg7 initiates Atg8 conjugation by catalyzing 
their C-terminal adenylation and conjugation to the catalytic cysteine of Atg3. 
Ultimately, the Atg12–Atg5-Atg16 complex catalyzes Atg8 ligation to a primary amino 
group on PE or other acceptor lipids.  
 
 Molecular mechanisms underlying Atg8 lipidation remain poorly understood 
despite association of Atg3, the E1 Atg7, and the composite E3 Atg12–Atg5-Atg16 with 
pathologies including cancers, infections, and neurodegeneration. The first part of this 
dissertation work describes methods for expressing and purifying human LC3 or 
GABARAP, ATG7, ATG3, and the ATG12–ATG5-ATG16L1 complex for in vitro 
studies of LC3/GABARAP lipidation; based on these protocol established, we report that 
an Atg3 element we term E123IR (E1, E2, and E3-interacting region) is an allosteric 
switch, by studying yeast enzymes. Nuclear magnetic resonance (NMR), biochemical, 
crystallographic and genetic data collectively indicate that in the absence of the 
enzymatic cascade, the Atg3E123IR makes intramolecular interactions restraining Atg3’s 
catalytic loop, while E1 and E3 enzymes directly remove this brace to conformationally 
activate Atg3 and elicit Atg8 lipidation in vitro and in vivo. We propose that Atg3’s 
E123IR protects the E2~UBL thioester bond from wayward reactivity toward errant 
nucleophiles, while Atg8 lipidation cascade enzymes induce E2 active site remodeling 
through an unprecedented mechanism to drive autophagy. 
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CHAPTER 1.    INTRODUCTION 
 
  
Backgrounds 
 
 
Autophagy 
 
Autophagy is a major catabolic pathway by which eukaryotic cells degrade and 
recycle diverse cellular materials (Yang and Klionsky, 2010). Sectors of the cytosol are 
first sequestered within a double-membrane-bound autophagosome, and then degraded 
upon autophagosome fusion with the lysosome in higher eukaryotes or vacuole in yeast 
(Nakatogawa et al., 2009). Cargoes directed to autophagosomes for degradation include 
protein assemblies, organelles, misfolded macromolecules, debris, and pathogenic 
bacteria (Galluzzi et al., 2017; Gatica et al., 2018; Stolz et al., 2014) (Figure 1-1). 
Autophagy plays important roles in cellular responses upon various forms of stress 
including starvation, toxicities and pathogenic infections. It is an indispensable cell 
activity in context of homeostasis, cellular differentiation and development.   
Dysregulation of autophagy is associated with metabolic, neurologic, and oncologic 
disorders (Amaravadi et al., 2016; Dikic and Elazar, 2018; Levy et al., 2017; Mizushima 
et al., 2008)and human diseases, including cancer, Parkinson’s disease, Crohn’s disease, 
liposome storage disorders, and so forth (van Beek et al., 2018). 
 
 
The process of autophagy 
 
Autophagy is a tightly regulated multi-stage activity, which can be dissected 
into 6 steps: initiation, phagophore nucleation, phagophore membrane expansion and 
cargo engulfment, autophagosome fusion with the vacuole or lysosome, cargo 
degradation, and recycling of the processed materials (Mizushima, 2007). Triggered by 
a wide range of signaling pathways, autophagy is initiated by activation of the unc-51-
like kinase (ULK) complex. This step sequentially activates the phosphoinositide 3-
kinase (PI3K) complex and Atg9 which collectively mediate the phagophore 
nucleation (Lane et al., 2017). Once the nucleation is completed, membrane from 
multiple potential sources, for example mitochondria (Lyamzaev et al., 2018; Rambold 
and Lippincott-Schwartz, 2011), endosomes (Longatti et al., 2012; Puri et al., 2013), 
endoplasmic reticulum (ER) (Carlos Martín Zoppino et al., 2010), Golgi bodies 
(Bodemann et al., 2011; van der Vaart et al., 2010), and even plasma membrane 
(Ravikumar et al., 2010), gathers at the phagophore as forming a double membrane 
organelle called autophagosome (Carlsson and Simonsen, 2015). This process is 
followed by other autophagic machinery being recruited to the isolated membrane 
preparing for the membrane elongation. The key proteins include WD-repeat protein 
interacting with phospho-inositides (WIPI) proteins (Proikas-Cezanne et al., 2015) and 
the enzyme cascade required for Atg8 family protein lipidation (Rubinsztein et al., 
2012). Atg8 family is a distinct subgroup of the ubiquitin-like (UBL) proteins. They 
modify phagophore membrane lipids through a chemical reaction similarly to other  
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Figure 1-1. The process of autophagy. 
After Atg8/ LC3 family proteins being ligation to the phosphatidylethanolamine(PE) on 
phagophore membrane is followed by membrane elongation and engulfment, meanwhile 
autophagic cargos are recruited to the phagophore via Atg8 binding with a variety of 
specific adaptor proteins that recognize and interact with the cargos, forming a the double 
membrane vesicle termed as autophagoosome. Autophagosome fuses with lysosome (or 
vacuole in yeast) and utilizes the lysosomal hydrolases to degrade the cargos for re-
utilization. 
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ubiquitin-like protein ligations, featured by the glycine at the truncated C-terminus of 
Atg8 family proteins being covalently ligated to amino group of phosphatidy-
lethanolamine (PE) (Nakatogawa et al., 2007). Membrane-linked Atg8 family proteins 
not only participate in the phagophore elongation and fusion, but also promote 
autophagosome closure (Feng et al., 2014; Fujita et al., 2008a). Moreover, 
autophagosome-coated Atg8 family proteins are responsible for autophagic receptor 
recognition and recruitment. This activity is realized by a specific interaction, where a 
hydrophobic groove on Atg8 captures unique peptide sequences termed as the Atg8 
interactive motif (AIM, in yeast or fungi) or LC3 interactive region (LIR , in higher 
organisms) harbored by autophagic adaptors or other autophagy related binding 
partners (Birgisdottir et al., 2013). As phagophore membrane expands and cargo 
engulfment proceeds, autophagosome eventually seals, then most of Atg8 molecules 
are cleaved from the outer-membrane by Atg4  . In the next step, autophagosome first 
migrates with facilitation from the microtubule system, then fuse with vacuole or 
lysosome under the regulation of soluble N-ethylmaleimide-sensitive factor attachment 
protein receptor (SNARE), Rab family proteins, PI3K complex and Rubicon (Hikita et 
al., 2018). The inner membrane and the engulfed cargos of the autophagsome are 
therefore degraded by vacuolar or lysosomal hydrolases. Finally, the resulting 
metabolites are exported to the cytosol for reutilization. 
 
 
Atg8 family protein lipidation and autophagy 
 
Autophagy-related 8 protein (Atg8) family is conserved across eukaryotic species. 
Atg8 is the only family member found in yeast and other fungus, whereas other three 
subfamilies: microtubule-associated protein 1 light chain 3 (MAP1LC3 or LC3), γ-
aminobutyric acid receptor-associated protein (GABARAP) and Golgi-associated 
ATPase enhancer of 16 kDa (GATE-16) exist in higher organisms including animals and 
plants. Despite residue variation in several positions across the whole proteins, Atg8 
family members share major similarity in amino acid sequences and protein structures 
(Figure 1-2). Structural studies in different Atg8 family proteins, including, but not 
limited to, Atg8s from multiple yeast organisms and the human LC3 and GABARAP 
family members, have revealed significant conformational similarity to ubiquitin. 
However, comparing to other UBL family members, in addition to the globular ubiquitin 
domain, Atg8 family proteins feature an additional N-terminal tail with moderate 
flexibility which consists of two helices connected by a short linker (Figure 1-2).  
 
As described in 1.1.2, many facets of autophagy rely on Atg8 in yeast (or six 
LC3- and GABARAP-family ubiquitin-like proteins in higher eukaryotes, here referred 
collectively to Atg8 family members) and the E1-E2-E3 enzymatic cascade that links 
Atg8’s C-terminus to the primary amine group of phosphatidylethanolamine (PE) lipid 
molecules (Dikic, 2017; Ichimura et al., 2000; Shpilka et al., 2011, 2012). As initiation of 
the lipidation process, the C-terminal tail of Atg8 family protein is cleaved by Atg4, 
exposing a glycine residue at the very end accessible by nucleophiles. Under tight 
regulation of autophagic machinery, this truncated version of Atg8 forms a thioester 
bond-linked complex with Atg7 (E1) via sidechains of C-terminal glycine and Atg7  
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Figure 1-2. Structure comparison of Atg8 and LC3 to other ubiquitin like 
proteins. 
In addition to the globular domain that shared by all ubiquitin-like proteins, Atg8/LC3 
family proteins are featured by a N-terminal helical extension.  
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catalytic cysteine. Ultimately, lipidated Atg8 family members serve as bridges between 
membranes and the cytosol, where their ubiquitin-like fold domains recruit AIM or LIR 
sequences in a staggering array of partner proteins involved in various aspects of 
autophagy (Birgisdottir et al., 2013; Noda et al., 2010; Rogov et al., 2014; Wild et al., 
2014). These include regulators and effectors of autophagosome biogenesis that promote 
membrane tethering and growth of the autophagosome, as well as adaptor proteins that in 
turn recruit cargoes for degradation (Zaffagnini and Martens, 2016). Accordingly, Atg8 
and its conjugation system enzymes are essential for autophagy in yeasts, and autophagy 
is severely impaired in their absence in mammalian cells (Tsuboyama et al., 2016). 
Lipidated Atg8-family members have also been implicated in protein recruitment to 
membranes in processes that are unrelated to autophagy in mammalian cells. Therefore, 
given these important roles of Atg8 and its conjugation system enzymes, it is important to 
understand molecular mechanisms regulating Atg8 lipidation. 
 
 
The process of Atg8 lipidation 
 
The process of Atg8 lipidation largely follows the similar procedure of other 
ubiquitin-like protein ligation system, whereas the ubiquitin or ubiquitin-like protein is 
delivered through a three enzyme (E1, E2, and E3) cascade before being conjugated to 
the final substrate (Ohsumi and Mizushima, 2004). The UBL, or Atg8 processed by Atg4 
in this context, first uses its C-terminal glycine to generate a thioester bond with the 
catalytic cysteine in E1 Atg7 (Tanida et al., 1999); this E1-UBL complex is disassociated 
upon interacting with E2 Atg3, where UBL is transferred to E2 and forms a new thioester 
bond with the catalytic cysteine of E2 (Tanida et al., 2002); finally, facilitated by E3 
Atg12–Atg5-Atg16, UBL is discharged from E2 and ligated to the target amine group 
located within the substrate PE (Hanada et al., 2007; Walczak and Martens, 2013) 
(Figure 1-3). While many UBL family members are able to coordinate with diverse E2s 
and E3s, and target an even wider range of substrates, Atg8, however, stays strictly 
specific to E2-like protein Atg3, E3-like protein complex Atg12–Atg5-Atg16 and it's 
only lipid substrate - phosphatidylethanolamine (PE); Atg8 is also known as the only 
UBL that modifies amine group in lipid substrates other than lysines in protein substrates. 
 
Atg7, the E1 for Atg8, harbors a N-terminal domain (NTD) and a C-terminal 
domain (CTD) (Taherbhoy et al., 2011). Atg7 adenylation domain (AD), which is a 
subdomain of the CTD, mediates self-dimerization as ADs in the canonical E1, and is 
both structurally and functionally comparable to the canonical E1 AD dimers (Taherbhoy 
et al., 2011). The flat dimeric interface serves as a platform to interact with the UBL as in 
other E1s. However, lacking the E1’s signature ubiquitin-fold domain (UFD) but 
replacing it by the unique NTD, the overall structure of Atg7 is distinct from other E1s. 
Unlike canonical E1 using UFD to recruit E2, Atg7, as dimerized via AD, interacts with 
Atg3 core domain by one copy of NTD in cis, and meanwhile binds an exclusive motif in 
Atg3 that is absent in other canonical E2s by the other copy in trans (Taherbhoy et al., 
2011).  
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Figure 1-3. The process of Atg8 lipidation. 
The lipidation of Atg8/LC3 family protein utilizes E1-E2-E3 cascade similar to other 
ubiquitin-like protein conjugation system. Atg8 first forms a thioester intermediate with 
activated E1 Atg7; he thioester bond is nucleophilic attacked by Atg3 catalytic cysteine, 
resulting in breaking down of the Atg7-Atg8 bond and formation a new thioester bond 
between Atg8 with E2 Atg3 catalytic cysteine; in the final step, E3 Atg12–Atg5-Atg16 
facilitates Atg8 being discharged from Atg3 and ligated to PE.  
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The unique E2 for Atg8, Atg3, features a core domain that resembles other 
canonical E2 folds and harbors an E2 catalytic center including a topologically conserved 
catalytic cysteine (Yamada et al., 2007). In addition, it contains a 20-amino acid N-
terminal helical extension (N-term) with the ability of sensing membrane curvature (Nath 
et al., 2014), an approximately 100-amino acid unstructured insertion in the middle of the 
core domain termed as the flexible region (FR) (Yamada et al., 2007), and an unique 
handle region (HR) downstream of the catalytic cysteine (Yamada et al., 2007). Upon 
activation by the E3-like enzyme Atg12–Atg5-Atg16 complex, the Atg3 catalytic center 
undergoes conformational changes, during which the catalytic cysteine and its 
surrounding regulative residues are rearranged to positions favored by Atg8-ligation 
(Sakoh-Nakatogawa et al., 2013). However, the functions of the FR and HR in Atg8 
lipidation remain obscure, though human protein study suggested that a short motif 
within the FR adopts a helical folding upon binding to the E3 compartment ATG12 
(Metlagel et al., 2013). And such interaction is indispensable for LC3 conjugation 
activity. Due to lack of structural evidences, it is also unrevealed about the full 
conformational requirements to activate the Atg3~Atg8 thioester intermediate as well as 
the full picture of Atg3-Atg12–Atg5-Atg16 interaction.  
 
The E3-like enzyme Atg12–Atg5-Atg16 resembles the ubiquitin-like protein 
ligation process. As a ubiquitin-like protein itself, Atg12 is conjugated to the substrate 
Atg5 via an isopepetide bond, catalyzed by its E1 Atg7 and E2 Atg10 without 
involvement of an E3 (Hanada and Ohsumi, 2005; Ohsumi and Mizushima, 2004). Atg16 
later joins the Atg12–Atg5 complex as a non-covalent yet stable binding partner. Both 
human ATG5 and ATG16L were revealed to have intrinsic binding abilities to lipids 
(Lystad et al., 2019; Romanov et al., 2012). Taken together with the membrane curvature 
sensing function of the ATG3 N-terminal helix (Nath et al., 2014), this may indicates a 
potential recruiting mechanism of the Atg3~Atg8 intermediate to the phagophore 
membrane. Neither the Atg12–Atg5-Atg16 E3 complex nor its individual compartments 
shows conservation in sequence to any of the three families of E3 (the RING family, the 
HECT family, and the RBR family); studies in multiple organisms including human and 
yeast also reveal no structural similarity between Atg12–Atg5-Atg16 and other E3 
ligases. With these significant differences between autophagy and canonical E1, E2, and 
E3s, it is challenging to study the mechanism of Atg8 lipidation based on existing UBL 
conjugation models. On the other hand, all these distinctive features of the Atg8 
lipidation cascade give more significance to study Atg8 lipidation, not only to complete 
the puzzle of autophagic pathway, but also to expand the current understanding of 
ubiquitin-like protein modification machineries.  
  
 
Atg8 family protein lipidation cascade and diseases 
 
As a unique protein family serving as an interactive hub to recruit other proteins 
to the autophagic membrane, lipidated Atg8 family members are critical in many 
essential biological pathways. Previous studies have implemented mouse models 
deficient in core autophagy genes to investigate physiological and pathogenic effects.  
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Previous studies in human patients showed that ATG7 polymorphisms (SNPs) at 
100A > G and 25108G > A promote the severity of asthma, likely by inducing higher 
level of interleukin-8 (IL-8) secretion to the serum, which potentially causes systematic 
inflammation (Shao et al., 2017). Moreover, changes in ATG7 promotor region 
(11313449G > A, 11313811T > C, 11313913G > A and 11314041G > A) result in 
excessive expression of ATG7 protein, which correlates with aggravated brain damage in 
Parkinson disease patients (Chen et al., 2013). In addition, substitution of human ATG7 
Val471 with alanine has shown association with an average 4-year earlier Huntington 
disease (HD) onset in European patients (Metzger et al., 2010). 
 
Beside the E1 ATG7, all three compartments of the E3 Atg12–Atg5-Atg16 harbor 
significant functions in a wide collection of diseases including asthma, lupus, 
autoimmune disorder, bone disease, neuron degeneration, and cancer. The SNP localized 
in ATG5 putative promotor region (rs12201458) has been shown negative impacts on 
asthma prognosis, probably due to an increase in the total ATG5 level in nasal mucosal 
cells, which has been observed in both acute and long-term asthma patients (Martin et al., 
2012). Two of the ATG5 SNPs (rs6937876 and rs548234) were also linked to multiple 
risk factors in systemic lupus erythematosus (SLE) disease onset (Qi et al., 2018; Zhou et 
al., 2011). Regarding to Behcet disease (BD), one of the ATG5 genetic changes 
(rs573775) was proposed to have protective function by a study in a Chinese patient 
cohort (Zheng et al., 2015). Another SNP in ATG5 (rs2245214) is associated with 
enhanced chance of developing Paget disease of bone (PDB) (Usategui-Martín et al., 
2015). Even a subtle mutation E122D in ATG5 that leads to moderate structural changes 
causes ataxia (Kim et al., 2016). Moreover, studies in clinical patients also linked several 
ATG5 SNPs with higher hepatocellular carcinoma (HCC) risk (Shen and Lin, 2019). 
Atg16 also plays an indispensable role in numerous disease onset or progression. For 
example, different SNPs occurring at the same site of human ATG16L1 (rs2241880, 
T300), can confer various outputs in patient studies (Chen et al., 2015; Li et al., 2017a; 
Usategui-Martín et al., 2015). Change of the local deoxynucleotide to A, with an 
unchanged coding for T300, is related to increased risk of chronic obstructive pulmonary 
(COPD) (Chen et al., 2015). ATG16L1 C allele mutation at this site was shown associated 
with Paget disease of bone (Li et al., 2017a). Additionally, the G SNP coding for T300A 
was linked to the likelihood of developing Crohn disease (Chen et al., 2015). However, in 
another study, the T300A variant of ATG16L1 was associated with decreased risk of 
brain metastasis of in non-small cell lung cancer patients (Li et al., 2017a). Another 
ATG16L1 SNP rs4663402 has strong relation with greater hepatocellular carcinoma risk 
(Shen and Lin, 2019). Nonetheless, polymorphisms in ATG12 promotor region (Li et al., 
2017b) and protein coding region (Shen and Lin, 2019) result in enhanced occurrences of 
Parkinson disease and hepatocellular carcinoma in human respectively. 
 
 
Summary and Aims 
 
Autophagy is a fate-determining metabolic activity to recycle cellular material 
and to avoid cell death under unfavored external and internal conditions. During the 
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course of autophagy, ligation of Atg8 family protein to PE lipid on both side of the 
autophagsome membrane (Atg8 lipidation) serves as an indispensable and tightly 
regulated check point, which plays significant roles in phagophore nucleation, membrane 
extension, autophagosome engulfment, vacuole/lysosome fusing with autophagosome, 
and cargo recruiting. As such, in order to decipher autophagy in a comprehensive and 
detailed level, it is important for us to understand the molecular mechanism of Atg8 
family protein ligation to the membrane. 
 
In this study, we will introduce a variety of methods, including but not limited to 
biochemistry, structural biology and cell biology approaches, to investigate the molecular 
requirements for Atg8/LC3 lipidation in human as well as Saccharomyces Cerevisiae 
system. The results will potentially shed light on therapy development and drug design 
that target the Atg8 lipidation cascade serving for modulation of the autophagy pathway.  
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CHAPTER 2.    PRODUCTION OF HUMAN ATG PROTEINS FOR LIPIDATION 
ASSAYS 1 
 
 
Introduction 
 
In eukaryotic cells, autophagy is a tightly regulated process responsible for 
degrading and recycling cellular components, and eliminating toxic assemblies and 
pathogens by sequestering cargo within an autophagosome, which fuses with a lysosome 
(or vacuole in yeast) harboring hydrolytic enzymes (Klionsky, 2000; Wileman, 2013). 
Several key aspects of this regulation involve ubiquitin-like proteins (UBLs) in the Atg8 
family, which form LC3 and GABARAP subfamilies in higher eukaryotes. 
LC3/GABARAP proteins have molecular weights in solution of approximately 14–17 
kDa, but their electrophoretic migration is relatively accelerated upon ligation to lipids 
such as in autophagic membranes. LC3/GABARAP ligation to lipids (lipidation) plays 
numerous roles in regulation, including influencing the formation, maturation, and size of 
autophagosomes, as well as recruiting selected cargoes and regulatory proteins (Ichimura 
et al., 2000; Nakatogawa et al., 2007; Ohsumi and Mizushima, 2004; Tanida et al., 2008) 
 
LC3 and GABARAP lipidation is orchestrated by a UBL ligation system, 
specifically conjugating the carboxyl group of the C-terminal glycine of LC3/GABARAP 
to the amine group of phosphatidylethanolamine (PE) (or potentially other lipids such as 
phosphatidyl serine) in autophagic membranes (Hanada et al., 2007; Ichimura et al., 
2000; Klionsky, 2000; Sou et al., 2006; Tanida et al., 2004b, 2004c). This involves a 
specialized enzyme cascade, where ATG7 acts as the E1 and ATG3 acting as the E2 to 
produce covalent, reactive thioester-linked ATG3~LC3/GABARAP (“~” denotes 
thioester bond and “-” denotes a noncovalent complex) intermediates. Efficient lipidation 
requires an ATG12–ATG5-ATG16L1 multiprotein complex acting as the E3. Notably, 
formation of this E3-like assembly first requires a related conjugation cascade, wherein 
the UBL ATG12 is covalently conjugated to ATG5 by ATG7 acting as the E1 and 
ATG10 acting as the E2 (Hanada et al., 2007; Noda et al., 2013), and then the ATG12–
ATG5 binds ATG16L1 to achieve full E3-like activity toward ATG3~LC3/GABARAP 
intermediates. Mutations or dysfunction of proteins in the LC3/GABARAP lipidation 
cascade results in severe diseases and poor prognosis in various eukaryotic organisms 
including humans (Cadwell et al., 2009; Kim et al., 2016; Lenz et al., 2011; Moloughney 
et al., 2011; Reed et al., 2015; Tindwa et al., 2015; Wu et al., 2014; Xue et al., 2010). 
 
Given the importance of LC3 and GABARAP lipidation, and potential interest in 
targeting their conjugation for therapeutic purposes (Cheng et al., 2013; Puri and 
Chandra, 2014), purified proteins for assaying LC3/GABARAP lipidation and 
performing structural analyses would be useful (Kaiser et al., 2013; Metlagel et al., 2013, 
2014; Nath et al., 2014; Otomo et al., 2013; Sakoh-Nakatogawa et al., 2013; Taherbhoy 
 
 
1 Reprinted from final submission with permission. Zheng, Y., Qiu, Y., Gunderson, J.E.C., and Schulman, 
B.A. (2017). Production of Human ATG Proteins for Lipidation Assays. In Methods in Enzymology, 
(Elsevier), pp. 97–113. doi: 10.1016/bs.mie.2016.09.055 
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et al., 2011). However, our optimal expression and purification procedures differ between 
the human LC3/GABARAP lipidation components and their yeast counterparts (Qiu et 
al., 2013). Thus, in this chapter, we describe detailed methods for expression and 
purification of human ATG proteins involved in LC3/GABARAP lipidation, including 
ATG7, ATG3, ATG12–ATG5-ATG16L1, and a method for expressing LC3B as 
exemplary for the human Atg8 orthologues. 
 
 
 Expression of Human LC3B, ATG7, ATG3, ATG12–ATG5, and ATG16L1 
 
 
General overview of protein expression and purification 
 
LC3B (emblematic of LC3/GABARAP family members), ATG3, and ATG16L1 
were expressed as GST-fusion proteins in Escherichia coli, whereas ATG7 and the 
ATG12–ATG5 conjugate were expressed through distinct methods in insect cells (Berger 
et al., 2004). An overview of the subsequent purification strategies is shown in Figure  
2-1. 
 
 
Expression constructs 
 
A truncated version of LC3B, corresponding to residues 1-120 that form the 
activated form with a C-terminal glycine that is the site of chemical reactions (Tanida et 
al., 2004b, 2004c), is expressed from pGEX-4T-1 (Table 2-1, Figure 2-2a) in E. coli. 
Full-length ATG7 was expressed from a modified version of pFastBac, with TEV-
cleavable N-terminal GST tag (pFastBac-GST) (Table 2-1, Figure 2-2b) for expression 
in insect cells. Full-length ATG3 was expressed from a modified version of pGEX-4T-1 
harboring a cleavage site for TEV protease instead of thrombin between GST and ATG3 
(pGEX-TEV) (Table 2-1, Figure 2-2c), for expression in E. coli. A truncated version of 
ATG16L1 corresponding to residues 1-69 was expressed from pGEX-TEV (Table 2-1, 
Figure 2-2d) in E. coli. 
 
 The ATG12–ATG5 subcomplex corresponds to a truncated version of ATG12 
(residues 52–140) that comprises the ubiquitin-like domain (Hanada and Ohsumi, 2005) 
linked via an isopeptide bond between its C-terminus to Lys130 on full-length ATG5 
(Hanada et al., 2007; Otomo et al., 2013). The linkage between ATG12 and ATG5 is 
achieved by their coexpression with ATG7 and ATG10 in insect cells using the biGBac 
system (Weissmann et al., 2016). First, four separate plasmids were generated. The 
coding sequences were inserted into pLIB vectors, with ATG7, and ATG10 untagged, 
ATG5 harboring a N-terminal TEV cleavable His-tag, and ATG12 (52–140) with a N-
terminal TEV cleavable GST-tag (Table 2-1, Figure 2-2e). Next, GST-TEV-ATG12 
(52–140), His-TEV-ATG5, ATG10, and ATG7 along with the promoter and terminator 
from the pLIB vectors were sequentially amplified using primers d scribed in Weissmann 
et al., 2016, and coassembled into the pBIG1a vector (Table 2-1, Figure 2-2f) using the 
  
  12 
 
 
Figure 2-1. Flow-chart indicating the expression system and purification 
strategies for production of human ATG proteins for lipidation assays. 
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Table 2-1. Plasmids used to produce human ATG proteins for lipidation assays. 
 
Protein expressed Plasmids generated Functions 
LC3B (1-120) pGEX-4T-1-LC3B Protein expression in E. coli 
ATG7 pFastBac-GST-ATG7 To generate bacmid for protein 
expression in insect cells 
ATG3 pGEX-TEV-ATG3 Protein expression in E. coli 
ATG12 (52-
140)~ATG5 
pLIB-GST-TEV-ATG12 To generate pBIG1a plasmid 
pLIB-His-TEV-ATG5 To generate pBIG1a plasmid 
pLIB-ATG10 To generate pBIG1a plasmid 
pLIB-ATG7 To generate pBIG1a plasmid 
pBIG1a-ATG12-ATG5-
ATG10-ATG7 
To generate bacmid for protein 
expression in insect cells 
ATG16L1 (1-69) pGEX-TEV-ATG16L1 Protein expression in E. coli 
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Figure 2-2. Graphical representation of plasmids used in this study.  
a. pGEX-4T-1-LC3B for LC3B (1–120) expression in E. coli. b. pFastBac-GST-ATG7 to 
construct bacmid for ATG7 expression in insect cells. c. pGEX-TEV-ATG3 for ATG3 
expression in E. coli. d. pGEXTEV- ATG16L1 for ATG16L1 (1–69) expression in E. 
coli. e. pLIB plasmid containing a GSTTEV-ATG12 (52–140), His-TEV-ATG5, ATG10, 
or ATG7 expression cassette to generate pBIG1a plasmid. f. pBIG1a-ATG12-ATG5-
ATG10-ATG7 plasmid to construct bacmid for ATG12 (52–140)–ATG5 expression in 
insect cells.   
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 method of Gibson Assembly (Gibson, 2011; Gibson et al., 2009; Weissmann et al., 
2016). 
 
 All constructs were generated through transformation into DH5alpha (NEB), 
bacterial growth, minipreps, and verified by automated sequencing. The recommended 
antibiotic concentrations are: 100 μg/mL for ampicillin, 50 μg/mL for kanamycin and 
spectinomycin, 25 μg/mL for chloramphenicol, 10 μg/mL for tetracyclin, and 7 μg/mL 
for gentamycin. 
 
 
Protein expression 
 
 Expression in E. coli 
 
Plasmid was transformed into BL21-CodonPlus (DE3)-RIL E. coli competent 
cells (Agilent Technologies). Bacteria was plated on LB-agar with appropriate antibiotics 
and Incubated at 37°C for 12–18 h. The starter culture was prepared from a single colony 
in 5 mL LB medium with antibiotics, and was cultured at 37°C, 200 rpm for 10–16 h. 
Then 5 mL of starter culture was inoculated into 1 L LB medium with appropriate 
antibiotics. The cells were grow at 37°C, 200 rpm, and monitor closely by measuring the 
absorbance at 600 nm. When OD600 reaches 0.8–1.0, IPTG was added at a final 
concentration of 0.6 mM. Shaker temperature was reset to 18°C, allowing growing with 
shaking at 200 rpm for 16–20 h. 
 Expression in insect cells 
 
For GST-thrombin-LC3B, GST-TEV-ATG7, and GST-TEV-ATG3, glutathione-
affinity chromatography was directly applied to their corresponding cell lysates. To 
obtain GST-TEV-ATG12 (52–140)–His-TEV-ATG5-GST-TEV-ATG16L1 (1-69) 
complex, cell lysates from insect cells and bacteria were mixed at 1:1 volume ratio and 
incubated at 4°C for 10 min before processing. 
 
I washed Glutathione Sepharose 4B (GS4B, GE Healthcare Life Sciences) 3 times 
with 10 column volumes of wash buffer in a chromatography column at 4°C. 
Alternatively, the beads could also be washed with 3 volumes of wash buffer by 
centrifugation at 500 x g for 5 min at 4°C, decanting the wash buffer, and repeating 
twice. Suggested bead volumes: 0.75 mL per 1 L bacterial culture, or 2 mL per 1 L Hi5 
insect cell culture, which is appropriate for both GST and nickel beads and all species of 
ATG proteins described in this chapter. Wash buffer was the same as lysis buffer but 
without PMSF, aprotinin, leupeptin, or any other proteasome inhibitor. 
 
Lysate was incubated with washed beads. The mixture was gently rocked at 4°C 
for 2 h for GS4B beads or 1 h for nickel beads to allow full binding.  
 
Then lysate with beads were transferred into a Poly-Prep chromatography column 
(Bio-Rad) at 4°C. Lysate was allowed to flow through by gravity to generate an even 
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resin surface in column. Although the flow-through is unneeded in principle, it is a good 
practice to save the flow-through for troubleshooting in the event of problems. 
 
If the lysate-bead solution is too thick to pass through the column, I would 
centrifugate the solution in 50 mL tubes at 500 x g for 5 min at 4°C. The supernatant was 
collected as flow through. Pelleted beads was gently resuspended in 10 column volumes 
of wash buffer and washed following last step. 
 
Finally, resin was washed in column with 10 column volumes of wash buffer 
without disturbing the flat resin surface. This step was repeated 3 times. 
 
 
Protein Purification 
 
 
Preparation of cell lysate 
 
Bacteria cells were harvested by centrifugation at 5900 x g for 12 min at 4°C. 
Insect cells were harvested at 500 x g for 15 min at 4°C. 
 
Cell pellet was suspended in 15 mL lysis buffer per liter bacteria culture or 50 mL 
per liter insect cell culture. Lysis buffer for all proteins except the ATG12–ATG5 
subcomplex was: 25 mM Tris–HCl pH 7.6, 200 mM NaCl, 2.5 mM 
phenylmethanesulfonyl fluoride (PMSF), 5 mM 2-Mercaptoethanol (BME). Lysis buffer 
for ATG12–ATG5 complex was: 1 x PBS, 400 mM NaCl, 2.5 mM PMSF, 5 mM BME. 
Also add 20 mg/L aprotinin, 10 mg/L leupeptin, or a protease inhibitor cocktail of choice 
to insect cell lysis buffer. 
 
Bacteria cells was lysed by sonicating 7 times, or insect cells 3 times, 10 s each 
time with intermittent cooling on ice. 
 
Lysate was cleared by centrifugation at 32,000 x g for 1 h at 4°C. The supernatant 
was collected and kept on ice. 
 
 
Glutathione-affinity chromatography for LC3B, ATG7, ATG3, and ATG12–ATG5-
ATG16L1 
 
For GST-thrombin-LC3B, GST-TEV-ATG7, and GST-TEV-ATG3, glutathione-
affinity chromatography was directly applied to their corresponding cell lysates. To 
obtain GST-TEV-ATG12 (52–140)–His-TEV-ATG5-GST-TEV-ATG16L1 (1-69) 
complex, cell lysates from insect cells and bacteria were mixed at 1:1 volume ratio and 
incubated at 4°C for 10 min before processing. 
 
Glutathione Sepharose 4B (GS4B, GE Healthcare Life Sciences) was washed 3 
times with 10 column volumes of wash buffer in a chromatography column at 4°C. 
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Alternatively, the beads could also be washed with 3 volumes of wash buffer by 
centrifugation at 500 x g for 5 min at 4°C, decanting the wash buffer, and repeating 
twice. Bead volumes: 0.75 mL per 1 L bacterial culture, or 2 mL per 1 L Hi5 insect cell 
culture, which was appropriate for both GST and nickel beads and all species of ATG 
proteins described in this chapter. Wash buffer was the same as lysis buffer but without 
PMSF, aprotinin, leupeptin, or any other proteasome inhibitor. 
 
The lysate was mixed with washed beads. The mixture was gently rocked at 4°C 
for 2 h for GS4B beads or 1 h for nickel beads to allow full binding. 
 
Lysate with beads were transferred into a Poly-Prep chromatography column 
(Bio-Rad) at 4°C. Lysate were allowed to flow through by gravity to generate an even 
resin surface in column. Although the flow-through is unneeded in principle, it is a good 
practice to save the flow-through for troubleshooting in the event of problems. 
 
If the lysate-bead solution is too thick to pass through the column, I would 
centrifugate the solution in 50 mL tubes at 500 x g for 5 min at 4°C. The supernatant was 
collected as flow through. Pelleted beads was gently resuspended in 10 column volumes 
of wash buffer and follow last step. 
 
The resin was washed in column with 10 column volumes of wash buffer without 
disturbing the flat resin surface. This step was repeated 3 times. 
 
 
Protease-mediated elution from beads for purification of LC3B, ATG3, and ATG7 
 
Rough protein concentration of bead turbid solution was measured using Bio-Rad 
protein assay with a standard curve. Bovine serum albumin is a suitable standard. 10 μL 
of uncleaved sample was stored as a negative control for cleavage efficiency check 
before adding protease.  
 
Thrombin protease was added to LC3B (1 mg thrombin per 100 mg of total 
protein), or TEV protease to ATG7 and ATG3 (2 mg TEV per 100 mg total protein). The 
mixture was kept gently rotated on a rocking shaker overnight to allow full cleavage. To 
be certain that all desired protein is cleaved from the GST-tag, I examined the bead slurry 
by SDS-PAGE, using a 15% acrylamide gel and Coomassie-staining, comparing cleaved 
samples to uncleaved samples (LC3B: Figure 2-3, Lanes a and b; ATG7: Figure 2-4, 
Lanes a and b; ATG3: Figure 2-5, Lanes a and b).  
 
The slurry was transferred into an empty Poly-Prep chromatography column pre-
rinsed with wash buffer to collect flowthrough. When liquid completely passes through, 
another 1 column volume of wash buffer was applied on the top of resin. This second 
fraction containing residual protein was also collected.  
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Figure 2-3. 15% SDS-PAGE showing LC3B (1–120) at different steps of 
purification.  
Lane M shows the molecular weight markers. Lane a shows constituents of bead slurry 
after binding GS4B resin. Lane b shows constituents of bead slurry after thrombin 
treatment. Lane c shows final purified LC3B (1–120) after gel filtration chromatography. 
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Figure 2-4. 15% SDS-PAGE showing ATG7 at different steps of purification.  
Lane M shows the molecular weight markers. Lane a shows constituents of bead slurry 
after binding GS4B resin. Lane b shows constituents of bead slurry after TEV treatment. 
Lane c shows final purified ATG7 after gel filtration chromatography. 
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Figure 2-5. 15% SDS-PAGE showing ATG3 at different steps of purification. 
LaneMshows the molecular weight markers. Lane a shows constituents of bead slurry 
after binding GS4B resin. Lane b shows constituents of bead slurry after TEV treatment. 
Lane c shows purified ATG3 after anion ion exchange chromatography. Lane d shows 
final purified ATG3 after gel filtration chromatography.  
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Glutathione-mediated ATG12–ATG5-ATG16L1 elution from GS4B 
 
0.7 resin volume of GS4B elution buffer was gently applied on the top of resin 
surface while keeping stopcock closed. After a 10-min incubation, I opened the stopcock 
and collected the eluate in a tube. Steps above were repeat 6 times with elution fractions 
kept in separate tubes. GS4B elution buffer: wash buffer supplemented with 20 mM 
glutathione (reduced, free acid) (EMD Millipore), pH adjusted by NaOH solution to the 
same as wash buffer.  
 
Each eluted fraction were run on a 15% SDS-PAGE gel to determine which 
fractions contain the majority of target protein. Desired fractions were then pooled. 
 
 
Nickel-affinity chromatography, imidazole-mediated elution from nickel beads, and 
TEV cleavage to obtain ATG12 (52–140)–ATG5-ATG16L1(1-69) complex 
 
After glutathione chromatography and glutathione mediated elution, the excessive 
GST-TEV-ATG16L1 (1-69) was further removed by nickel affinity chromatography. 
 
HIS-Select Nickel Affinity Gel (Sigma-Aldrich) was washed 3 times with 10 
column volumes of wash buffer in a chromatography column at 4°C. Then nickel-affinity 
chromatography was performed to enrich the ATG5-bound complex. The glutathione 
elution of GST-TEVATG12 (52–140)-His-TEV-ATG5-GST-TEV-ATG16L1 (1-69) was 
applied to the HIS-Select Nickel Affinity Gel beads and was incubated following the 
same procedure described above for glutathione-affinity chromatography. An imidazole 
elution was performed following steps described in glutathione elution using nickel bead 
elution buffer (wash buffer supplemented with 100 mM imidazole pH 7.5). 10 μL 
uncleaved sample was stored as a negative control to check cleavage efficiency.  
 
TEV protease (2 mg TEV per 100 mg total protein) was added to the imidazole 
eluate. Then the eluate was dialyzed in wash buffer while performing cleavage overnight 
at 4°C. Cleavage completeness was examined by SDS-PAGE, using a 15% acrylamide 
gel and Coomassie-staining (Figure 2-6, Lanes a and b). The cleaved GST and HisMBP 
tags were removed from ATG12 (52–140)–ATG5-ATG16L1 (1-69) complex by further 
cation ion exchange purification described below. 
 
 
Ion exchange chromatography on ATG3 and ATG12(52–140)~ATG5-ATG16L1 (1-
69) 
 
Anion ion exchange was performed to tag-free ATG3 and cation ion exchange to 
tag-free ATG12 (52–140)–ATG5-ATG16L1 (1-69) accordingly to their isoelectric 
points, before ultimately purifying by gel filtration chromatography. This step is optional 
for LC3B and ATG7.  
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Figure 2-6. 15% SDS-PAGE showing ATG12 (52–140)–ATG5-ATG16L1 (1-69) 
complex at different stages of purification.  
Lane M shows the molecular weight markers. Lane a shows elution from nickel-affinity 
chromatography, capturing His- and His-MBP tags on ATG5 and ATG16L1 (1–69), 
respectively. This is the second step in the purification, following an initial purification 
by glutathione affinity chromatography to capture GST-tag on ATG12. Lane b shows 
product of TEV cleavage reaction preformed during dialysis. Lane c shows final purified 
ATG12 (52–140)_ATG5-ATG16L1 (1–69) complex after subsequent cation ion 
exchange and gel filtration chromatography.  
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A 5 mL HiTrap SP (cation exchange) or a Q (anion exchange) HP column (GE 
Healthcare Life Sciences) was equilibrated on an AKTA FPLC (GE Healthcare Life 
Sciences) in 95% buffer A with 5% buffer B. Cation exchange buffer A: 25 mM HEPES 
pH 7.0, 5 mM DTT. Anion exchange buffer A: 25 mM Tris–HCl pH 8.0, 5 mM DTT. 
Buffer B corresponded to buffer A with additional 1 M NaCl. The protein samples was 
diluted with buffer A to a final NaCl concentration of 50 mM. Samples were clarified by 
centrifugation at 4000 x g for 5 min at 4°C before loading onto a FPLC system. If loading 
is through a sample pump, I would equilibrate the sample pump in buffer A. The ATG 
proteins described in this chapter can be concentrated to 10 mg/mL if desired to reduce 
volume prior to loading onto FPLC. 
 
After equilibration, the sample was loaded onto column with a suggested loading 
rate of 2 mL/min. After loading, the column was washed by 5 column volumes of 95% 
buffer A with 5% buffer B. After all unbound sample was washed out, I initiated 
gradient, raising buffer B proportion from 5% to 50% over 25 column volumes at 2 
mL/min flow rate, and collecting fractions with a volume of 2 mL. 
 
Peak fractions was examined by SDS-PAGE with Coomassie-stained 15% 
acrylamide gels to determine which fractions contain the majority of the ATG proteins 
(the combined fractions of ATG3 is shown in Figure 2-5, Lane c; ATG12–ATG5-
ATG16L1 is not shown). 
 
 
Gel filtration chromatography for LC3B, ATG7, ATG3, and ATG12–ATG5-
ATG16L1 
 
Superdex 200 10/300 GL columns (GE Healthcare Life Sciences) were used for 
all the ATG proteins described here, except for LC3B using a Superdex 75 10/300 GL 
column (GE Healthcare Life Sciences). Protein samples of LC3B and ATG7 used in this 
step were directly collected from protease cleavage, while ATG3 and ATG12–ATG5-
ATG16L1 were pre-purified by ion exchange. 
 
A Superdex 75/200 column was equilibrated on an AKTA FPLC system with 
storage buffer (25 mM Tris–HCl pH 7.6, 200 mM NaCl, 5 mM DTT). NaCl 
concentration was icreased to 500 mM in the buffer used for LC3B, or to 300 mM in the 
buffer used for ATG12 (52-140)–ATG5-ATG16L1 (1-69). 
 
Then the protein samples were concentrated by Amicon Ultra Centrifugal Filter 
Units (EMD Millipore) with appropriate molecular weight cutoff. Resulting concentrated 
protein samples were transferred to one or multiple 1.7 mL microcentrifuge tubes. 
Centrifugation was performed at 16,000 x g for 10 min at 4°C to clarify samples before 
loading onto a FPLC system. 
 
1-2 mL clarified protein sample was loaded onto a Superdex 200 column, 
followed by gel filtration run in storage buffer. The fractions were collected in 0.5 mL 
volume size. 
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The peak fractions were examined by SDS-PAGE with Coomassie-stained 15% 
acrylamide gels to determine which fractions contain the majority of the ATG proteins. 
Desired fractions were pooled (the pooled fractions of LC3B, ATG7, ATG3, and 
ATG12–ATG5-ATG16L1 are shown in Figure 2-3, Lane c; Figure 2-4, Lane c; Figure 
2-5, Lane d; Figure 2-6, Lane c, respectively). 
 
 
Storing Purified Proteins 
 
Purified proteins was concentrated to approximately 10 mg/mL and stored in 20 
μL aliquots at - 80°C after flash-freezing in liquid nitrogen. They can be thawed on ice 
for use and refreezed for storage up to twice to ensure protein activity. 
 
 
Concluding Remarks 
 
Proteins prepared as described earlier are eligible for multiple biochemical assays, 
including LC3B lipidation. In our experience, aliquots of purified ATG proteins stored at 
- 80°C are stable for up to a year, giving consistent results in assays for LC3B lipidation, 
formation of thioester bonded ATG7~LC3B and ATG3~LC3B intermediates, binding 
using BioLayer Interferometry (Octet Red, ForteBio) or isothermal titration calorimetry 
(ITC), and for structural studies using NMR and crystallography. 
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CHAPTER 3.    A SWITCH ELEMENT IN THE AUTOPHAGY E2 ATG3 
MEDIATES ALLOSTERIC REGULATION ACROSS THE LIPIDATION 
CASCADE 2 
 
 
Introduction 
 
The central enzyme in the Atg8 lipidation cascade is the E2, Atg3 (Klionsky, 
2000; Wileman, 2013). Atg3 receives Atg8 from the E1 Atg7, to form a covalent, 
reactive Atg3~Atg8 intermediate linked by a thioester bond (referred to by ~) between 
the C-terminus of Atg8 and the catalytic Cys of Atg3. Atg8 is then transferred from the 
Atg3 catalytic Cys to PE in a reaction catalyzed by a composite E3 enzyme (Fujita et al., 
2008b)4/15/2020 10:13:00 AM containing another autophagy UBL, Atg12, conjugated to 
Atg5 (Hanada et al., 2007). In vitro, the yeast Atg12–Atg5 conjugate is sufficient to serve 
as an E3 enzyme activating lipidation of Atg8 (Hanada et al., 2007). Atg16 binding to 
lipids substantially enhances E3 activity (Lystad et al., 2019) and is required in vivo 
(Mizushima et al., 1999) to localize Atg12–Atg5 to the preautophagosomal structure that 
precedes autophagosome formation (Kim et al., 2001; Suzuki, 2001), through many 
mechanisms (Harada et al., 2019; Kaufmann et al., 2014; Romanov et al., 2012). 
 
The prior structure of Atg3 from S. cerevisiae revealed a catalytic core domain 
(Atg3cat) largely resembling E2s for canonical UBLs such as Ub, NEDD8 and SUMO, 
including a long central helix and two catalytic segments (Yamada et al., 2007) (Figure  
3-1a). One segment harbors the catalytic Cys234, and the other displays Thr213, which 
also is essential for the lipidation reaction and corresponds to the canonical E2 catalytic 
Asn that plays a crucial structural role (Berndsen et al., 2013; Ichimura et al., 2000; 
Sakoh-Nakatogawa et al., 2013). In addition, Atg3 displays unique, functionally-
important structures (Nath et al., 2014; Yamada et al., 2007; Yamaguchi et al., 2010): an 
N-terminal amphipathic membrane-binding helix (N, residues 1-18); an intrinsically-
disordered flexible region (FR, residues 85-159); a handle region consisting of a helix 
and a disordered region (HR, residues 237-282) that contains an Atg8-interacting motif 
that is dispensable for the lipidation reaction but plays important roles in vivo; and a 
flexible extreme C-terminal extension (C, residues 299-310). While prior structural 
studies showed how Atg7 engages Atg3cat and the Atg3FR for Atg8 transfer to Atg3 
(Hong et al., 2011; Noda et al., 2011; Taherbhoy et al., 2011; Yamaguchi et al., 2012), 
less is understood about subsequent roles of the autophagy E3. A crystal structure showed 
how the human E3 enzyme recruits a peptide-like region from Atg3’s FR, but this FR 
motif is not conserved across Atg3 sequences from many organisms, including yeasts 
(Metlagel et al., 2013). Furthermore, the structure lacked Atg3’s catalytic domain, for 
which prior studies of cysteine accessibility in the yeast enzyme suggested that the 
autophagy E3 triggers a structural rearrangement that affects the orientation of the  
 
 
2 Reprinted from final submission with open access permission. Zheng, Y., Qiu, Y., Grace, C.R.R., Liu, X., 
Klionsky, D.J., and Schulman, B.A. (2019). A switch element in the autophagy E2 Atg3 mediates allosteric 
regulation across the lipidation cascade. Nature Communications 10, 1–14. https://doi-org.ezp-
prod1.hul.harvard.edu/10.1038/s41467-019-11435-y 
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Figure 3-1. The Atg12–Atg5 module within the autophagy E3 activates intrinsic 
reactivity of the Atg3~Atg8 intermediate. 
a, Structures of yeast Atg3 (left, PDB 2DYT), a ubiquitin E2 (middle, UBE2D1, PDB 
4AP4), and their superimposition (right). Atg3 unique elements are indicated by colors 
shown in schematics of Atg3 constructs used in this study (below). b, Intrinsic reactivity 
of Atg3~Atg8 intermediate monitored by pulse-chase discharge to NH2OH in presence of 
indicated E3 variant. c, Close-up of structural superimposition of yeast Atg12–Atg5-
Atg16 (PDB 3W1S) and corresponding human complex with ATG3FR (PDB 4NAW). 
Residues from yeast Atg12 corresponding to the human ATG3FR-binding site are shown 
as red sticks. d, Effects of mutations in minimal yeast E3 (Atg12–Atg5) on stimulating 
Atg3~Atg8 discharge, monitored by quantification of Atg3~Atg8 remaining after 2.5 
minutes in pulse-chase assays using the scheme as in b, as a function of NH2OH 
concentration. (Error bar: STDEV, N = 3) Representative gel is shown in Supplemental 
Figure 3-2b.   
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catalytic Cys234 relative to Thr213 (Sakoh-Nakatogawa et al., 2013). The molecular 
underpinnings for E3-dependent conformational activation remains elusive. 
 
Here we use a hybrid structural approach integrating information from 
biochemistry, NMR, crystallography, and yeast genetics to identify a molecular basis for 
Atg3 allosteric activation. Overall, the data suggest that a distinct peptide-like element 
acts like a brace mediating intramolecular interactions with the Atg3 catalytic domain to 
restrict the conformation of the active site and prevent reactivity toward errant 
nucleophiles, while the E3 elicits an unprecedented E2 activation mechanism by remotely 
binding to this brace to couple other E3 interactions with allosteric activation of active 
site mediating Atg8 lipidation. 
 
 
Methods 
 
 
Protein sequence alignment 
 
ScAtg3 and HsATG3 protein sequence alignment are done by CLUSTALW 
online. 
 
 
Protein expression and purification 
 
Detailed methods for cloning, expressing and purifying yeast proteins Atg8, Atg3 
(and their mutants or truncated versions) and Atg16 (residues 1-46) were described 
previously (Kaiser et al., 2013; Taherbhoy et al., 2011; Zheng et al., 2017). For Atg7 
proteins, full-length Atg7 or a fragment containing residues 1-289 (NTD) was inserted 
into the pGEX-4T-1 vector following the Gibson Assembly protocol (Gibson et al., 
2009), and transformed into BL21 competent E. coli; protein expression and purification 
protocols for Atg7 WT and mutants resemble those for Atg3 and Atg8. To obtain purified 
E3 complex, N-term 6X His-tagged Atg12 100-186 and untagged Atg5 1-284 were 
inserted into the two multiple cloning sites (MSCs) of pRSF-Duet-1 respectively, 
whereas Atg7 1-630 and Atg10 were inserted into the MSCs of pET-Duet-1. The two 
plasmids are co-transformed into BL21 competent E. coli to produce His-Atg12–Atg5. 
Bacteria culture were grown at 37 ˚C to reach O.D. 1.5, followed by 0.6 mM IPTG 
induction at 23 ˚C overnight. Cells are harvested in 1X PBS, 400 mM NaCl and lysed by 
sonication. Ni-NTA resin (Qiagen) was incubated with lysate for 1 hour then washed 3 
times with the same buffer. His-Atg12–Atg5 were eluted by buffer with 200 mM 
imidazole and immediately purified by cation exchange chromatography on an S column 
(GE Healthcare). Purified his-Atg12–Atg5 were combined with Atg16 1-46 in a 1:2 
molar ratio and further purified by size-exclusion chromatography on a Superdex-200 
column (GE Healthcare) to harvest peak factions containing the final product of His-
Atg12–Atg5-Atg16.  
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Crystallization and data collection  
 
1 μL purified Atg3∆NFR protein sample was manually loaded onto a glass hanging-
drop cover and overlaid with 1 μL of precipitant solutions. Crystal was harvested from 
100 mM HEPES pH 7.2, 150 mM L-malic acid, 9% PEG3350. Crystals were allowed to 
grow at 4 ˚C for 5-7 days to reach their maximum sizes. All crystals were harvested by 
loops with 25% glycerol in addition to growth solution, and stored in liquid nitrogen for 2 
days until data collection. 
 
 
Data collection, processing, and structure refinement 
 
Data for Atg3∆NFR was collected at Advanced Photon Source (APS) Ser-CAT 
beamline 22-BM. The Dataset was created from single crystals, and was processed and 
scaled in HKL2000. Phase was solved by molecular replacement. Search model for 
Atg3∆NFR was modified from Atg3FL (PDB 2DYT) with Atg3E123IR manually removed. 
Model was built in Coot (Emsley et al., 2010), and refinements were primarily performed 
in Refmac (Murshudov et al., 1997) and finalized in Phenix (Adams et al., 2010). 
 
 
Simulated annealing omit map generation 
 
In order to avoid the model bias, we generated a simulated annealing omit map 
for the catalytic cysteine region. First, residue 231-237 in the final-refined model was 
deleted; then, the model with deletion was subjected to 3 rounds of refinement in 
Phenix62 with simulated annealing running from 5000K to 300K in 50 steps. Finally, the 
Fo-Fc map was shown at 3σ level along with the deleted residues in the model. 
 
 
Atg3 C234 and Atg8 G116C disulfide crosslinking 
 
All the cysteines except C234 within Atg3 were mutated to alanines. 800 μM 
Atg8 K26P C22V G116C was reduced by 20 mM DTT, desalted into buffer 1 (20 mM 
HEPES pH 7.5, 50 mM NaCl), immediately mixed with 1:1 v/v buffer 2 (20 mM HEPES 
pH 7.5, 50 mM NaCl, 2.5 mM 2,2’-dipyridyldisulfide (DPS). DPS stock was pre-
dissolved in a minimal amount of DMSO), incubated at room temperature (R.T.) for 20 
min, and desalted again into buffer 1. Meanwhile, 500 μM Atg3 was reduced by 20 mM 
DTT and desalted into buffer 1, immediately mixed with DPS-Atg8 at a 1:2 molar ratio, 
and incubated at R.T for 1 hour. Crosslinking product was purified by anion exchange 
chromatography on Q column (GE Healthcare) and size-exclusion chromatography on a 
Superdex-200 column (GE Healthcare).  
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NMR spectroscopy 
 
All the experiments were conducted at 25 ˚C with protein samples dissolved in 20 
mM MES pH 6.5, 100 mM NaCl, and 10% v/v D2O on either a Bruker Avance 600-MHz  
 
or 700-MHz or 800-MHz spectrometer equipped with a 5-mm triple resonance 
cryoprobe and a single-axis pulse field gradient. For resonance assignments of backbone 
atoms, 3D triple-resonance experiments were measure either with 0.4 mM 13C, 15N, 2D-
labeled or 13C, 15N-labeled Atg3cat, 0.75 mM 13C, 15N-labeled Atg3FR 86-159, and 0.4 mM 
13C, 15N-labeled Atg8 K26P, C33V, G116C. The backbone assignment of Atg3cat was 
carried out using 3D HNCACB, HNcoCACB, HNCO, HNcaCO along with 15N-resolved 
[1H, 1H] NOESY spectra. The backbone of Atg3FR 86-159 fragment peptide was assigned 
using 3D HNCACB, CACBcoNH, HNCO, HNcaCO along with HNcocaNH spectra. The 
backbone assignment of Atg8 K26P, C33V, G116C was carried out using 3D HNCACB, 
HNcoCACB, HNCO, HNCA and HNcoCA along with 15N-resolved [1H, 1H] NOESY 
spectra. Spectra were processed with Topspin 3.5 or nmrPipe and analyzed using CARA. 
All chemical shift perturbation analyses were done using [15N, 1H] TROSY spectra, and 
the perturbations were calculated using the formula CSP (ppm) = 
((δH)^2+0.2*(δN)^2)^0.5. Titration experiments were done using 0.1 mM 15N-labeled 
Atg3FR 86-159 (or its I132D,L135D,I136D mutant) titrated with 0-150 μM Atg12–Atg5, 
0-500 or 0-625 μM Atg3∆FR, or 0 and 0.2 mM unlabeled Atg3∆FR C234~Atg8 K26P, 
C33V, G116C disulfide complex; 0.1 mM 15N-labeled Atg3cat was titrated with 0 or 4.4 
mM unlabeled Atg3FR 123-147. Also spectrum from 0.1 mM 15N-labeled Atg8 was 
compared with 0.1 mM disulfide complex of unlabeled Atg3cat cross-linked via C234 to 
15N-labeled Atg8 K26P, C33V, G116C. The CSP value is used in the titration plots to get 
the Kd values using the equation: y=(y0+x)/(x+Kd), where x is the concentration and Kd 
is the dissociation constant and y0 is a constant. 
 
Since most of the resonances in Atg3FR mutant [I132D, L135D, I136R] have the 
same chemical shifts as that of Atg3FR, the assignment of Atg3FR was used to assign the 
resonances of Atg3FR mutant. The assignment of the mutated residues and the 
neighboring ones that shifted the most ambiguously shifted to positions where new peaks 
appeared. 
 
 
Liposome preparation 
 
2.5 mg of E. coli polar lipid extract (Avanti) was dissolved in chloroform, solvent 
evaporated using a nitrogen stream, and re-dissolved in 250 μL 20 mM HEPES pH 7.0, 
150 mM NaCl buffer. Product was passed through 100 nm nuclepore membrane 
(Whatman) installed in a mini extruder (Avanti) 15 times to obtain 10 mg/mL 
homogenized liposomes in solution.  
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In vitro pulse-chase assay for Atg3~Atg8 discharge to NH2OH 
 
Shortly before the starting the experiment, Atg3 and mutants were reduced with 
20 mM DTT and desalted by Zeba columns (Thermo Fisher Scientific) into reaction 
buffer. In the pulse step, 5 μM Atg7, 20 μM Atg3, 40 μM Atg8, 1 μM ATP and 1 μM 
MgCl2 were mixed in 25 μL 20 mM HEPES pH 7.0, 150 mM NaCl buffer. After 1 hour, 
pulse reactions were quenched by adding Apyrase. In chase step, 5 μL of each pulse 
product was incubated with 5 μL chase solution containing 5 μM Atg12–Atg5-Atg16 and 
a course of NH2OH at R.T. for 2.5 minutes, or with liposome at a final concentration of 2 
mg/mL added in a timely manner. Samples were analyzed by 4%-12% Bis-Tris Protein 
Gels (Thermo Fisher Scientific) and stained with Coomassie Brilliant Blue. All raw data 
are available in the source data file. 
 
 
In vitro assay for Atg8 lipidation 
 
Atg3 and mutants were reduced and desalted as described in the pulse-chase 
assay. Reactions were performed at 30 ˚C in 25 μL volumes of 20 mM HEPES pH 7.0, 
150 mM buffer, with 1 μM Atg7, 2 μM Atg3, 5 μM Atg8, 5 μM Atg12–Atg5-Atg16, 1 
mM ATP, 1 mM MgCl2 and 1 mg/mL liposome, and were monitored in timely manner. 6 
μL of each reaction was mixed with 6 μL 2X protein loading buffer. Samples were 
analyzed using a by 15 % urea gel at 4 ˚C and stained with Coomassie Brilliant Blue. All 
raw data are available in the source data file. 
 
 
Yeast strains, vectors, media and growth conditions 
 
The XLY161 and the YCY131 (Cao et al., 2009) cells were transformed with 
pRS416 vectors harboring HA-tagged Atg3 (WT or mutants); the YCY131 cells were co-
transformed with pRS414-Atg7-Atg10-Atg8∆R. For nutrient-rich conditions, yeast cells 
were grown in synthetic minimal (SMD; 0.67% yeast nitrogen base, 2% glucose, and 
auxotrophic amino acids and vitamins as needed) medium. For nitrogen starvation, cells 
were first cultured in appropriate SMD medium to mid-log phase; they were then shifted 
to the SD-N medium (0.17% yeast nitrogen base without ammonium sulfate or amino 
acids, 2% glucose). The XLY161 cells were cultured in SMD-Ura to mid-log phase 
before they were shifted to SD-N medium for 2 h; The YCY131 cells were cultured in 
SMD-Ura-Trp to mid-log phase before they were shifted to SD-N medium for 4 h. All 
raw data are available in the source data file. 
 
 
Western blot 
 
1 OD of each of the yeast cultures was harvested and lysed in 50 μl MURB (50 
mM NaH2PO4, pH 7.0, 2.5 mM MES, pH 7.0, 1% SDS, 3 M urea, 0.5% β-
mercaptoethanol, 1 mM NaN3, 0.2 μg/μl bromophenol blue) by vortexing them with 
glass beads at 4°C for 5 min. The samples were then heated at 70°C for 10 min before 
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they were loaded onto and run in SDS-PAGE gels, followed by transferring onto PVDF 
membranes. The membranes were blocked with 5% skim milk, probed with primary 
antibodies (1:3000, Atg8; 1:10000, Dpm1; 1:3000, HA; and 1:10000, Pgk1), and then 
probed with horseradish peroxidase (HRP)-coupled secondary antibodies (1:10000, anti-
rabbit and anti-mouse antibodies). Atg8 antiserum was generated by injecting purified 
yeast Atg8 peptides into rabbits; Dpm1 antibody is purchased from Molecular Probes 
(catalog# A-6429); antibody to the HA epitope is from Sigma (catalog# H3663); Pgk1 
antibody is a generous gift from Dr. Jeremy Thorner, University of California, Berkeley. 
Goat anti-rabbit HRP sencondary antibody is from Fisher (catalog# ICN55676), and 
rabbit anti-mouse HRP sencondary antibody is from Jackson ImmunoResearch (catalog# 
315-035-003). Chemiluminescence images were obtained by developing films in a dark 
room. The standard-sized protein bands from the protein ladder lanes on the blots were 
correspondingly hand-drawn using a pen onto the developed films. The hand-drawn 
protein ladders were not shown in the figures, but they can be found in the corresponding 
source files. 
 
 
Results 
 
 
Autophagy E3 activates intrinsic reactivity of Atg3~Atg8 
 
 E2~UB and E2~UBL intermediates are activated in distinct ways by different 
classes of E3 enzymes(Buetow and Huang, 2016; Cappadocia and Lima, 2018; Zheng 
and Shabek, 2017) . Many E3s, for example RING and related E3s for UB, NEDD8 and 
SUMO, and SIM-containing SUMO E3s, allosterically promote noncovalent interactions 
between the E2 and UB (or UBL) moieties within the covalent intermediate. This is often 
monitored by an E3 increasing the susceptibility of an E2~UB or E2~UBL intermediate 
to nucleophilic attack by a nonspecific amine nucleophile (Saha and Deshaies, 2008). In 
contrast, HECT and RBR E3s use a different mechanism that depends on positioning the 
E2-bound UB for transfer to the E3 catalytic Cys. Although the autophagy E3 lacks 
homology to UB, NEDD8, and SUMO ligases, we asked whether there are common 
mechanistic features by testing biochemical activities of the relatively simplistic Atg8 
pathway from S. cerevisiae. Potential E3-mediated stimulation of intrinsic activity of the 
Atg3~Atg8 intermediate was examined by adapting the pulse-chase assay format used to 
study canonical UB enzymes (Figure 3-1b). Briefly, a pulse-reaction catalyzed by Atg7 
generated the thioester-linked Atg3~Atg8 intermediate. After quenching this reaction 
with apyrase, increasing concentrations of hydroxylamine were added (Figure 3-1b). 
Discharge of the Atg3~Atg8 intermediate to this nonspecific amine nucleophile was 
monitored by appearance of free Atg3 in SDS-PAGE. Whereas the Atg3~Atg8 
intermediate was relatively stable on its own, addition of Atg12–Atg5 stimulated 
discharge. This activation was maintained in the presence of Atg16, while Atg5-Atg16 
alone was insufficient (Figure 3-1b). Atg12–Atg5 is also known to be required for E3 
activation of the lipidation reaction (Hanada et al., 2007; Lystad et al., 2019; Sakoh-
Nakatogawa et al., 2013). Thus, within the composite autophagy E3 is a module that 
activates the intrinsic reactivity of the Atg3~Atg8 thioester-linkage. 
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 As a first step toward understanding the mechanism, we performed mutagenesis 
based on the prior structure showing that in the context of the human autophagy E3, 
Atg12 recruits a short peptide-like region of Atg3’s FR (Metlagel et al., 2013). Although 
the FR sequences from human and yeast Atg3 are not conserved (Figure 3-2a), the 
structures of human and yeast Atg12–Atg5 superimpose well, including the Atg3FR-
binding site (Figure 3-1c) (Noda et al., 2013; Otomo et al., 2013). Mutations in the 
corresponding surface of yeast Atg12–Atg5 not only impair Atg8 lipidation but also 
intrinsic activation of the Atg3~Atg8 intermediate (Figure 3-1d and Figure 3-2b,c). 
Thus, it seems probable that the FR from yeast Atg3 likewise contains an E3-binding 
element. 
 
 
Identification of an E3-binding element in yeast Atg3 
 
A multi-tiered approach was used to identify the Atg3 element determining E3 
activation and binding. First, given that the corresponding E3-binding element from 
human Atg3 is located in the FR, a panel of Atg3 variants harboring individual or 
multiple alanine mutations in the FR were monitored for E3-dependent Atg3~Atg8 
discharge (Figure 3-3a and Figure 3-4). Second, mutants hindering discharge were 
tested for relevance to autophagy, by testing for effects on E3-dependent Atg8 lipidation 
in vitro and in vivo (Figure 3-3b,c). Finally, NMR was used to define the Atg3FR region 
mediating E3-binding. After resonances were assigned for a construct spanning the entire 
intrinsically-disordered Atg3FR (residues 86-159), an unlabeled version of the Atg12–
Atg5 conjugate was added, and [15N, 1H] TROSY spectra were examined for chemical 
shift perturbation and/or line-broadening as an indicator of binding (Figure 3-5a,c). 
Although other residues in Atg3’s FR contribute to activity (Figure 3-3a), the major 
region implicated by all assays spans from Ile129-Lys142 (Figure 3-3a-c and Figure 3-
5a,c). For reasons described below, we termed this region Atg3E123IR. 
 
 
Atg3’s E3-binding element also binds E1 and E2 
 
  Prior studies showed that the region corresponding to Atg3E123IR mediates Atg3 
recruitment to the autophagy E1, Atg7 (Noda and Klionsky, 2008; Taherbhoy et al., 
2011). In this upstream step of the conjugation cascade, Atg3E123IR binding to Atg7’s N-
terminal domain (Atg7NTD) anchors the complex, thereby increasing the local 
concentration for distal, transient interactions between Atg7’s and Atg3’s catalytic 
domains for Atg8 transfer between them (Kaiser et al., 2013) (Figure 3-6a). To further 
confirm that as in the human autophagy pathway (Ohashi and Otomo, 2015; Qiu et al., 
2013), E1 and E3 binding to Atg3 is mutually exclusive for yeast enzymes, we examined 
the ability of the isolated NTD from Atg7 to compete with Atg12–Atg5-dependent 
activation of Atg3~Atg8. The wild-type Atg7NTD inhibits the E3-dependent reaction, 
whereas a version harboring a mutation (P283D) previously shown to impair Atg3 
binding (Figure 3-6a) (Taherbhoy et al., 2011) does not show this inhibitory effect, 
consistent with mutually-exclusive binding (Figure 3-6b). 
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Figure 3-2. Lack of sequence conservation for Atg3 FR yet functional 
conservation of FR-binding site on Atg12 within Atg12–Atg5 E3 module. 
a, Sequence alignment of Atg3 from S. cerevisiae (yeast) and H. sapiens (human). 
Elements in yeast Atg3 are labeled. b, Representative gel image of 3 times repeated 
assays from Figure 3-1d. c, Effects of indicated Atg12 Ala mutants in predicted FR-
binding site from Atg12–Atg5 on Atg8 lipidation in vitro, in reactions with Atg7, Atg12–
Atg5-Atg16, and liposomes generated from E. coli polar lipids as a source PE, and 
detected by migration of Atg8 in Coommassie-stained SDS-PAGE gel.  
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Figure 3-3. E123IR plays essential role in E3-dependent Atg8 ligation activity. 
a, Effects of indicated Ala mutants in Atg3’s FR on E3 (Atg12–Atg5-Atg16) activation 
of Atg3~Atg8 intermediate, quantified as percent Atg3~Atg8 remaining in pulse-chase 
discharge to NH2OH over 2.5 minutes. Locations of most defective and moderately 
defective mutants are indicated on schematics, and those corresponding to Atg3E123IR are 
shown in red. b, Effects of indicated Ala mutants in Atg3’s FR on Atg8 lipidation in 
vitro, in reactions with Atg7, Atg12–Atg5-Atg16, and liposomes generated from E. coli 
polar lipids as source of PE, and detected by migration of Atg8 in Coommassie-stained 
SDS-PAGE gel. c, Effects of indicated Ala mutants in Atg3’s FR on Atg8 lipidation in 
vivo, as detected by western blot for Atg8 after 2 hours starvation of XLY161 
atg3∆pep4∆ strain of S. cerevisiae expressing either WT or mutant HA-tagged Atg3. 
Pgk1 is loading control for Atg8, Dpm1 is loading control for Atg3.  
  
  35 
 
 
Figure 3-4. Alanine scan within FR of Atg3 for E3-dependent activation of 
Atg3~Atg8 intermediate. 
Representative gel image of assay from Figure 3-3a.  
 
 
 
 
 
 
Figure 3-5. E123IR interacts with autophagy E3. 
a, [15N, 1H] TROSY spectra of 15N-labeled Atg3FR titrated with unlabeled Atg12–Atg5-
Atg16. b, Estimated binding affinities between E123IR residues and Atg12–Atg5, based 
on Chemical Shift Perturbations (CSPs) observed upon titrating increasing concentrations 
of Atg12–Atg5. c, Chemical shift perturbations plotted as a function of Atg3FR residue 
numbers, with resonances showing intermediate exchange line broadening indicated by 
stripes.  
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Figure 3-6. E123IR binds the E1 Atg7 and E2 core domain Atg3cat. 
a, Close-up showing interactions between Atg3E123IR and N-terminal domain (NTD) of 
Atg7 (PDB 3T7G). b, Effects of Atg3E123IR-binding WT Atg7 NTD and non-binding 
mutant (P283D) on E3-stimulated intrinsic reactivity of Atg3~Atg8 intermediate, as 
monitored by pulse-chase discharge to NH2OH. c, [15N, 1H] TROSY spectra of 15N-
labeled Atg3cat alone (red) or in 1:44 mixture with unlabeled Atg3FR (cyan), with 
Chemical Shift Perturbations (CSPs) plotted per residue below. d, [15N, 1H] TROSY 
spectra of 15N-labeled Atg3FR titrated with unlabeled Atg3∆FR, with representative (1:5 
molar ratio Atg3FR vs Atg3∆FR) CSPs plotted per residue below. e, Estimated binding 
affinities between E123IR residues and Atg3∆FR, based on CSPs observed upon titrating 
increasing concentrations of Atg3∆FR. f, Residues corresponding to greatest CSPs are 
shown as spheres on the structure.  
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 Intriguingly, this same E1 and E3-binding Atg3E123IR element was also found to 
contact the Atg3cat domain in the prior crystal structure of full-length Atg3 alone, 
although the interactions were previously attributable to crystal packing and not tested 
further (Figure 3-1a) (Yamada et al., 2007). To address the potential for bona fide 
interaction in solution, we wished to perform NMR. This first required generation of 
suitable fragments from Atg3, because in prior studies of the full-length protein, it was 
not possible to detect resonances from the catalytic domain due to dramatically different 
dynamic properties from the FR region (Yamada et al., 2007). Thus, the isolated Atg3cat 
domain was prepared (construct listed in Figure 3-1a), and resonances observed in [15N- 
1H] TROSY spectra were assigned (Figure 3-6c). Intriguingly, resonances corresponding 
to the active site loop (residues 232-236) were not assignable in the spectrum, potentially 
due to motions on the millisecond or intermediate exchange time scales.  
 
 [15N-1H] TROSY spectra obtained upon adding a synthetic peptide corresponding 
to the Atg3FR element to 15N-labeled Atg3cat (Figure 3-6c), or upon adding an unlabeled 
version of Atg3∆FR to 15N-labeled Atg3FR (Figure 3-6d), showed substantial chemical 
shift perturbations. In both titrations, the perturbed resonances correspond to the Atg3FR 
and Atg3cat domain residues observed to interact in the crystal structure (Figure 3-6f). 
Consistent with the interactions, Introduction of mutations to hydrophobic residues I132, 
L135, and I136 significantly diminished the chemical shift perturbations within E123IR 
(Figure 3-7a), and further lower the E123IR-Atg3∆FR binding affinity (Figure 3-7b). 
Thus, the NMR data confirmed the Atg3E123IR element as a bona fide Atg3cat-binding 
element in solution. The term Atg3E123IR reflects this being an E1, E2, and E3 interacting 
region. 
 
Compared to the interaction with Atg12–Atg5 (Figure 3-5b), we observed lower 
binding affinity between E123IR and Atg3∆FR (Figure 3-6e). To gain insights into the 
structure of E123IR in its free form, we examined the ΔδCα − ΔδCβ secondary chemical 
shifts, which show this element is not a helix in isolation (Figure 3-7c) (Marsh et al., 
2006). It seems likely that a combination of different affinities for different partners, and 
intrinsic conformational plasticity could enable switching between E1, E2, and E3-bound 
states. 
 
 
Active site loop conformation in absence of Atg3E123IR  
 
 To illuminate roles of Atg3E123IR-binding to the Atg3cat, we determined a crystal 
structure lacking these interactions for comparison to the prior structure of full-length 
Atg3. The structure of a version of Atg3 lacking the N-terminal 18 residues and the FR 
region (Atg3∆NFR) (Figure 3-8a, Figure 3-9a, and Table 3-1), determined at 2.5 Å 
resolution, superimposes well overall with that of full-length Atg3 (0.48 RMSD over C-
alphas) (Figure 3-8b). However, there are substantial differences in the catalytic Cys 
loop and adjacent regions. As described previously, in the structure of full-length Atg3, 
the catalytic Cys234 is sequestered in a pocket formed by side chains from the HR and 
two loops (Yamada et al., 2007). This orientation is catalytically incompetent, with the 
Cys distal from the structurally-important Thr213 and from two other side-chains 
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Figure 3-7. Mutations in E123IR hydrophobic residues significantly impair 
E123IR-Atg3 interaction. 
a, [15N, 1H] TROSY spectra of 15N-labeled Atg3FR titrated with increasing 
concentrations of unlabeled Atg3∆FR, with chemical shift perturbations (CSPs) plotted per 
residue shown below for one representative point in the titration (1:5 molar ratio Atg3FR 
mutant versus Atg3∆FR). b, Calculated binding affinities between Atg3∆FR and residues in 
the I132D,L135D,I136D mutant version of Atg3FR, based on CSPs along the titration. c, 
The ΔδCα − ΔδCβ secondary chemical shifts of the Atg3FR peptide in its free form.  
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Figure 3-8. Conformational changes upon E123IR removal from Atg3. 
a, Crystal structure of Atg3∆NFR (PDB 6OJJ, from this study). b, Superposition of 
Atg3∆NFR (PDB 6OJJ, light blue with catalytic Cys shown in green) with prior structure 
of Atg3FL (cyan, PDB 2DYT) with E123IR and catalytic Cys shown in red, and 
differences highlighted in cartoons. c, Fo-Fc map shown at 3σ after omitting the catalytic 
cysteine region (residues 231-237) of Atg3∆NFR and performing simulated annealing. d, 
Close-ups of catalytic elements from Atg3∆NFR and Atg3FL. e, Close-up superposition of 
Atg3∆NFR (light blue) and Atg3FL (cyan) structures, showing interactions between Atg3’s 
catalytic domain and E123IR, and conformational rearrangements upon E123IR 
dislocation.  
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Figure 3-9. Structural remodeling of the Atg3 catalytic core upon displacement or 
removal of the E123IR element. 
a, Stereo view of Atg3∆NFR crystal structure in 2Fo-Fc density map, σ=1.0. b, Schematics 
of structures of Atg3, with E123IR bound (from Atg3FL PDB 2DYT), with E123IR 
removed in Atg3ΔNFR (this study, PDB 6OJJ), and with E123IR dislodged upon binding 
to Atg7 (PDB 4GSL), with the conformation in the Atg7-bound complex shown to the 
right for comparison to the structure with the E123IR deleted shown in Figure 3-8d. c, 
Superposition of the structure of Atg3ΔNFR (this study, light blue, PDB 6OJJ) and Atg3FL 
(cyan PDB 2DYT) shows potential rearrangement of Atg3’s extreme C-terminal element 
between E123IR-bound and -displaced forms of Atg3. Residues not visible in the prior 
structure are highlighted with spheres for alpha carbons. The conformation of Atg3’s 
extreme C-terminal residues observed in the Atg3ΔNFR structure is incompatible with 
E123IR binding due to clashing, and is consistent with NMR chemical shift perturbations 
of this region detected by NMR in Figure 3-6.   
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Table 3-1. Data collection and refinement statistics 
 
Parameters Atg3∆NFR 
(ScAtg3 ∆1-18, ∆86-159) 
Data collection 
Space group C 1 2 1 
Cell dimensions  
a, b, c (Å) 92.078, 44.557, 66.2 
α, β, γ (°)  90, 102.977, 90 
Resolution (Å) 30-2.40 (2.44-2.40)* 
Rmerge 0.050 (0.766) 
I / σ (I) 7.9 (1.1) 
CC 1/2 0.996 (0.587) 
Completeness (%)  92.6 (77.3) 
Redundancy 3.4 (2.8) 
  
Refinement 
Resolution (Å) 26.41-2.50 
No. reflections 9090 
Rwork / Rfree 0.2127 / 0.2427 
No. atoms 1519 
Protein 1458 
Water 61 
B factors (Å2) 51.20 
Protein 51.24 
Water 50.23 
R.m.s. deviations 
Bond lengths (Å) 0.006 
Bond angles (˚) 0.918 
*Values in parentheses are for highest-resolution shell. 
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 (Tyr179 and His232) that are important for the lipidation reaction (Figure 3-8d, right) 
(Kaiser et al., 2013; Sakoh-Nakatogawa et al., 2013; Yamada et al., 2007). By contrast, in 
the absence of the Atg3E123IR element, Atg3’s catalytic center is structurally rearranged 
into an activated conformation through a domino-like effect that ultimately results in 
remodeling a loop observed in full-length Atg3 into an additional helical turn at the N-
terminus of the HR (Figure 3-8e); the remodeled helix cannot restrain the side-chain 
from catalytic Cys234, thereby allowing the alternative orientation where Cys234 is 
surrounded by additional key catalytic residues (Figure 3-8d, left). Moreover, it appears 
that the extreme C-terminal region of Atg3 also rearranges between the E123IR-bound 
and other states: this element undergoes a conformational change and additional C-
terminal residues are visible in the crystal structure of Atg3∆NFR relative to the prior 
structure of full-length Atg3. In the conformation in Atg3∆NFR these residues would clash 
with the bound E123IR (Figure 3-9b,c), although their nearby location also suggests 
potential to positively interact with the E123IR in an alternative, presently unknown 
conformation. Indeed, resonances from these residues display large NMR chemical shift 
perturbations when 15N labeled Atg3cat is titrated with the unlabeled FR (Figure 3-6c). 
 
 
Mutants displacing Atg3E123IR from Atg3cat activate ligation 
 
 Interestingly, the activated orientation of the catalytic center was observed 
previously in structures of full length Atg3 when bound to Atg7 (Figure 3-9b) (Kaiser et 
al., 2013; Yamaguchi et al., 2012). Although interpreted as stemming from indirect Atg7 
interactions with the backside of Atg3’s catalytic domain (Kaiser et al., 2013; Yamaguchi 
et al., 2012), and/or from the high pH of the crystallization conditions (Sakoh-
Nakatogawa et al., 2013), reinterpretation of the crystal structures with the knowledge 
that the Atg3E123IR element binds Atg3’s catalytic domain in solution leads to a 
prediction: interactions with Atg3E123IR would allosterically restrict Atg3’s catalytic 
domain. However, displacement of the Atg3E123IR element, either by deleting the FR 
domain (Figure 3-8d), or upon binding to the E1 Atg7 during formation of the 
Atg3~Atg8 intermediate (Figure 3-9b), or upon binding to the Atg12–Atg5 portion of E3 
for the lipidation reaction (Sakoh-Nakatogawa et al., 2013), would enable the active 
conformation. Nonetheless, relevance for the lipidation would depend on the Atg3E123IR 
element binding in the context of an Atg3~Atg8 complex. We tested this concept by 
NMR. First, a stable proxy for Atg3∆FR~Atg8 was made with a disulfide bond between a 
Cys replacement for the C-terminal Atg8 residue and the catalytic Cys in Atg3∆FR 
(Atg3∆FR-S-S-Atg8). Upon adding this to the 15N-labeled Atg3FR, we observed the similar 
chemical shift perturbations in [15N, 1H] TROSY spectra of 15N-labeled Atg3FR (Figure 
3-10a) as for Atg3 alone (Figure 3-6d). 
 
If binding to the Atg3E123IR would be inhibitory, then mutations in catalytic 
domain residues that mediate this interaction and that are not needed for other Atg3 
functions should stimulate the lipidation reaction in the absence of E3. Therefore, based 
on the crystallographic (Figure 3-8e) and NMR data (Figure 3-6f), we generated several 
Ala substitutions designed to disrupt the autoinhibitory interactions as follows: Asp133,  
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Figure 3-10. Mutations in E123IR-binding residues activate Atg3~Atg8 in the 
absence of E3 in vitro and in vivo. 
a, [15N, 1H] TROSY spectra of 15N-labeled Atg3FR alone (red) or in 1:2 mixture with 
unlabeled, disulfide-bonded proxy for Atg3∆FR~Atg8 (purple), with Chemical Shift 
Perturbations (CSPs) per residue shown below. b, Locations of mutations a-e designed to 
impair interactions between Atg3’s catalytic domain and E123IR shown on crystal 
structure of Atg3 (PDB 2DYT). c, Effects of indicated mutants in Atg3 catalytic domain-
E123IR interface on intrinsic E3-independent activity of Atg3~Atg8 intermediate. 
Quantification is of WT or indicated mutant versions of Atg3~Atg8 remaining after 2.5 
minutes as a function of NH2OH concentration in pulse-chase assays, without E3, 
repeated 3 times repeats average. (Error bar: STDEV, N = 3) Representative gel is shown 
in Figure 3-11. d, Effects of indicated mutants in Atg3 catalytic domain-E123IR 
interface on E3-independent Atg8 lipidation in vitro, in reactions with Atg7, Atg12–
Atg5-Atg16, and liposomes generated from E. coli polar lipids as a source PE, and 
detected by migration of Atg8 in Coommassie-stained SDS-PAGE gel. e, Effects of 
indicated mutants in Atg3 catalytic domain-E123IR interface on E3-independent Atg8 
lipidation in vivo, as detected by western blot for Atg8 after 4 hours starvation of the 
YCY131 multi-Atg knockout strain of S. cerevisiae expressing Atg7, Atg10, Atg8∆R 
(activated in absence of Atg4) and either WT or mutant HA-tagged Atg3.  
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which is the only residue in the Atg3E123IR that does not bind Atg7 and thus could form an 
Atg3~Atg8 intermediate, interacts with the HR in full-length Atg3; Arg251 and Arg254 
in the HR; Lys292, Thr295, and Ser296 in the Atg3cat domain; and Gln302, His303, and 
Asp304 or Glu308 and Trp310 at the extreme C-terminus (Figure 3-10b). These 
mutations mimicked effects of adding E3 to the in vitro reactions lacking E3: relative to 
wild-type Atg3, they activate the Atg3~Atg8 thioester-bonded intermediate (Figure  
3-10c and Figure 3-11) and the lipidation reaction (Figure 3-10d), but are either not 
affected or defective for E3-dependent activity (Figure 3-3b and Figure 3-12c). The 
defect for one mutant in E3-dependent activity can be explained due to its location in the 
E123IR (D133A), but other mutants do not map to a region presently known to be 
required for activity, although they may reflect an activated conformation of the 
Atg3~Atg8 intermediate. If this were the case, then the activation observed in the absence 
of E3 may even be lower than theoretically possible. 
 
Notably, increased Atg3~Atg8 discharge was not observed upon adding 
liposomes together with the isolated Atg7NTD that like E3 also binds the Atg3E123IR 
(Figure 3-11). Thus, releasing the Atg3E123IR from the Atg3cat domain may not be 
sufficient for activating the lipidation activity of the Atg3~Atg8 intermediate. A potential 
difference between binding of the Atg7NTD versus Atg12–Atg5, or the effects of E3-
mimicking mutations, would be if the latter alter internal structural dynamics of the 
Atg3~Atg8 intermediate so as to increase susceptibility to nucleophilic attack. 
 
To test the effects of the activating mutants in vivo, it is necessary to examine 
Atg8 lipidation in the absence of the proteins comprising the E3. We also wished to 
minimize confounding effects of Atg8, Atg3, and the Atg12–Atg5-Atg16 complexes 
interacting with many proteins associated with autophagy and non-autophagy-related 
pathways. Thus, we generated a minimal system for examining Atg8 lipidation in vivo, 
with a plasmid expressing Atg7, HA-tagged versions of Atg3, and the processed form of 
Atg8 in a yeast strain in which these and 21 other autophagy (Atg) genes have been 
deleted (MKO) (Cao et al., 2009). Atg8 lipidation was markedly increased with the 
majority of the mutants (Figure 3-10e), which is remarkable given the complexity of 
events required for the reaction and the large number of other proteins that interact with 
Atg3 and Atg8 in vivo. 
 
 
Extensive surfaces are required for Atg3~Atg8 activation 
 
To identify the portions of Atg8 and the Atg3 catalytic domain contributing to the 
activated state, we performed mutagenesis. E3-dependent discharge was monitored for 28 
mutant versions of Atg8 and 27 mutant versions of Atg3, each having one to four Ala 
replacements for surface residues (Figure 3-12a,b and Figure 3-13a,b). The Atg8 
mutations together probed the majority of its surface, while Atg3 mutations encompass 
the catalytic domain that is structurally homologous to canonical E2s and the short C-
terminal extension. A strikingly large fraction of the mutants affected activation of Atg8 
discharge. Notably, the majority of the most defective mutants were also defective for  
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Figure 3-11. Mutations in interface between Atg3’s E123IR element and catalytic 
domain activate the Atg3~Atg8 intermediate.  
Representative gel image of assay from Figure 3-10c.  
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Figure 3-12. Alanine scan within Atg3cat and Atg8 by NH2OH discharge assays. 
a, Representative gel image of assay from Figure 3-13a. b, Representative gel image of 
assay from Figure 3-13b.  
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Figure 3-13. Extensive surfaces of Atg8 and the Atg3 catalytic domain are required 
for activation of the Atg3~Atg8 intermediate.  
a, E3-dependent activation of Atg3~Atg8 intermediate testing roles of indicated surfaces 
through multiple-Ala scanning mutagenesis over Atg3’s catalytic domain. Quantification 
is of WT or indicated mutant versions of Atg3~Atg8 remaining after 2.5 minutes as a 
function of NH2OH concentration in pulse-chase assays, with Atg12–Atg5-Atg16 as E3. 
b, E3-dependent activation of Atg3~Atg8 intermediate testing roles of indicated surfaces 
through multiple-Ala scanning mutagenesis over Atg8, performed as in a. c, Effects of 
covalent Atg3 complex formation with Atg8, as detected by comparing 15N, 1H] TROSY 
spectra of 15N-labeled Atg8 G116C (red) alone and disulfide-bonded complex with 
Atg3cat as a proxy for Atg3cat~Atg8 intermediate (cyan), with chemical shift perturbations 
per Atg8 residue shown below. Stripes indicate resonances with line-broadening due to 
intermediate exchange.   
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Atg8 lipidation in vitro (Figure 3-14a,b) and in vivo (Figure 3-14c). For Atg3, the 
defective mutants map to a large continuous surface encompassing Atg3’s ?1-, HR-, and 
?5- (large central), ?4- (adjacent to the catalytic center) helices, and C-terminal 
extension (Figure 3-15b). For Atg8, the mutations map to two major surfaces. One 
corresponds to the canonical UBL hydrophobic patch and C-terminus, and the other to 
the Atg8-specific groove that binds AIM/LIR sequences in partner proteins (Figure  
3-15c). 
 
We hypothesized that some of the mutational defects could reflect impaired 
interactions between Atg8 and Atg3 in the covalent intermediate. Thus, we performed 
NMR considering that prior studies of intrinsically active E2~UB intermediates showed 
chemical shift perturbations indicating noncovalent interactions between the covalently 
linked E2 and UB moieties. Thus, we compared [15N, 1H] TROSY spectra for 15N-labled 
Atg8 harboring a C-terminal Cys alone versus in a disulfide-bonded complex linked to 
the active site of unlabeled Atg3cat – i.e., in a stable proxy for the Atg3cat~Atg8 
intermediate (Figure 3-13c). 
 
The striking similarity between the locations of Atg8 NMR resonances shifting 
upon covalent complex formation with Atg3 (Figure 3-15c), and of mutants impairing 
E3-activated discharge from Atg3 (Figure 3-15b) raise the possibility of noncovalent 
interaction in a so-called closed conformation. We used structural modeling to consider 
potential parallels between the activated Atg3~Atg8 intermediate and a RING E3-E2~UB 
complex as representative. First, the structure of Atg3 was superimposed with the 
homologous region of the E2 UBE2D1 in the intermediate, and then the UB-fold domain 
of Atg8 was docked onto the linked UB (Figure 3-15a). Next, the locations of mutations 
impairing activity, and NMR chemical shift perturbations in the Atg3cat~Atg8 complex, 
were analyzed, and found to be in striking concordance with the corresponding interface 
residues in canonical E2~UB intermediates (Figure 3-15b,c,d). The notable exceptions 
were the AIM/LIR docking site in Atg8, Atg3 residues corresponding to E3-binding 
regions of canonical E2s, and the extreme C-terminus of Atg3. These regions are not 
shared between Atg3 and canonical E2s, and the latter region is not fully visible in the 
crystal structures presumably due to potential to adopt different conformations. 
Nonetheless, the differences for the autophagy-specific regions that are observed between 
the crystal structures (Figure 3-9c), and in NMR chemical shift perturbations (Figure  
3-6c), for the E123IR-bound and other forms of the Atg3 catalytic domain are consistent 
with roles in allosteric regulation. Indeed, in using the Atg3∆NFR crystal structure for the 
structural model, the C-terminal residues of Atg3 approach the docked Atg8. On this 
basis, it is tempting to speculate that this sequence, Met-Glu-Gly-Trp, would adopt a 
reverse AIM/LIR motif anchoring Atg8 to Atg3 in a closed conformation. Concordantly, 
mutation of these residues has amongst the most deleterious effects (Figure 3-13a and 
Figure 3-12a, 3-14a), although future studies will be required to visualize the structure of 
the E3-activated Atg3~Atg8 intermediate.  
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Figure 3-14. Alanine mutants within Atg3cat and Atg8 examined by Atg8-
lipidation assays in vitro and in vivo. 
a, Effects of indicated mutants defective in a on E3-dependent Atg8 lipidation in vitro, in 
reactions with Atg7, Atg12–Atg5-Atg16, and liposomes generated from E. coli polar 
lipids as a source PE, and detected by migration of Atg8 in Coommassie-stained SDS-
PAGE gel. b, Effects of indicated mutants defective in b on E3-dependent Atg8 lipidation 
in vitro, in reactions with Atg7, Atg12–Atg5-Atg16, and liposomes generated from E. 
coli polar lipids as a source PE, and detected by migration of Atg8 in Coommassie-
stained SDS-PAGE gel. c, Effects of indicated mutants defective in a on Atg8 lipidation 
in vivo, as detected by western blot for Atg8 after 2 hours starvation of the XLY161 
atg3∆pep4∆ strain of S. cerevisiae expressing either WT or mutant HA-tagged Atg3. 
Dpm1 is loading control.  
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Figure 3-15. Modeling of the active conformation of Atg3~Atg8 intermediate. 
a, Generation of model for a potential closed E2~Ubl conformation for Atg3~Atg8, with 
structures of Atg3∆NFR (PDB 6OJJ, from this study) and Atg8 (PDB 2ZPN) superimposed 
on E2 and Ub, respectively, in a RING E3-E2~Ub complex (PDB 4AP4). b, Sites of 
Atg3 mutations impairing E3-dependent activation of Atg3~Atg8, mapped on model for 
closed conformation. Red – residues corresponding to E2~Ub interface in closed 
conformation; wheat – residues corresponding to RING E3 binding site; bronze – 
residues in catalytic segment. c, Sites of Atg8 mutations impairing E3-dependent 
activation of Atg3~Atg8, mapped on model for closed conformation. Red – residues 
corresponding to E2~Ub interface in closed conformation; orange – residues 
corresponding to AIM/LIR-binding site. d, Atg8 residues showing chemical shift 
perturbation one standard deviation above the mean upon covalent complex formation 
with Atg3, mapped on model for closed conformation. Red – residues corresponding to 
E2~Ub interface in closed conformation; orange – residues corresponding to AIM/LIR-
binding site. 
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Data Availability 
 
The coordinates and structure factors for Atg3∆NFR have been deposited to the 
RCSB Protein Data Bank with ID 6OJJ for immediate release upon manuscript 
publication. The resonance assignments for Atg3cat, Atg3FR (residues 86-159), and Atg8 
have been deposited to the Biological Magnetic Resonance Data Bank with the IDs 
27922, 27923, and 27924, respectively for immediate release upon manuscript 
publication.  
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CHAPTER 4.    DISCUSSION 
 
 
Here we demonstrated that Atg3 is restrained by an E123IR element within its 70-
residue flexible region bracing the active site; this brace establishes regulation by 
interacting with E1 (Figure 3-6a) (Taherbhoy et al., 2011), E2 (Figure 3-6c,d,f), and E3 
(Figure 3-5a,c); and that a key function of the autophagy E3 Atg12–Atg5-Atg16 is to 
bind this brace to activate the intrinsic reactivity of the thioester-bonded Atg3~Atg8 
intermediate (Figure 3-6b) (Zheng et al., 2019). This unprecedented allosteric 
mechanism underlying E2 activation - revealed by our NMR, crystallographic, and 
mutational data, taken together with prior studies - addresses the longstanding question of 
how Atg8 lipidation is activated by an E3 that lacks sequence and mechanistic 
conservation with canonical conjugation enzymes. Notably, E1-binding to the E123IR 
element is not sufficient to activate the Atg3~Atg8 intermediate (Figure 3-11), 
suggesting additional roles for E3 other than binding. Meanwhile, NMR data raise the 
possibility that Atg3’s active site residues undergo conformational motions on a different 
time-scale from the rest of catalytic domain, which could impact enzymatic activity 
(Figure 3-6c). Taken together, we speculate that E3 binding to the Atg3~Atg8 
intermediate broadly influences dynamic or structural features of Atg3’s catalytic domain 
that in turn bias the active site in favor of the reactive conformation. Indeed, the need for 
E3-binding to activate the Atg3~Atg8 intermediate in vitro is partially ameliorated by 
mutations that map to the surfaces in and adjacent to the Atg3cat-Atg3E123IR interface 
(Figure 3-10c,d and Figure 3-11). Physiological relevance is supported by such mutants 
also activating E3-independent lipidation in vivo (Figure 3-10e).  
 
Although future studies will be required to visualize downstream steps in the 
reaction cascade, we propose that Atg8 lipidation involves Atg7, Atg3, and Atg12–Atg5-
Atg16 toggling their common interacting region in Atg3 as follows: 1) Prior to 
encountering the Atg7~Atg8 intermediate, the Atg3E123IR binds to the Atg3 catalytic 
domain to protect the catalytic Cys from access by non-specific cellular molecules. 2) 
The Atg7~Atg8 intermediate binds to Atg3’s E123IR element using Atg7’s N-terminal 
domain. This mediates both E1-E2 interactions and conformational activation of Atg3’s 
catalytic Cys to receive Atg8 from Atg7. 3) Following formation of the Atg3~Atg8 
intermediate, Atg3’s E123IR element could re-engage the Atg3 catalytic domain to 
prevent Atg8 mis-ligation to a non-specific nucleophile. We speculate that this may also 
prevent the extreme C-terminal residues of Atg3 from prematurely adopting a 
conformation that contributes to the activate conformation of the Atg3~Atg8 
intermediate. 4) With relatively higher binding affinity, the Atg12–Atg5 portion of the 
autophagy E3 subsequently dislodges Atg3’s E123IR, which enables structural 
remodeling of the active site loop from a sequestered position to an exposed 
conformation where the catalytic Cys is juxtaposed with surrounding side-chains that are 
crucial for Atg8 lipidation (Figure 4-1). Apparently, Atg12–Atg5 further activates the 
lipidation reaction in a manner involving extensive surfaces from both Atg3 and Atg8 in 
the Atg3~Atg8 intermediate. In parallel with the mechanisms how RING and SUMO E3 
activate canonical E2~UBL intermediates (Buetow and Huang, 2016; Cappadocia 
andLima, 2018; Zheng and Shabek, 2017) , we speculate that the autophagy E3  
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Figure 4-1. Schematic model for allosteric regulation of Atg3 activity through 
E123IR interactions across the lipidation cascade. 
The autophagy E2 Atg3 is autoinhibited by AtgE123IR. When Atg3 encounters E1 Atg7, 
E123IR is relocated upon binding to Atg7NTD, thereby triggering rearrangement of the 
Atg3 catalytic core to activate Cys234 for attacking the Atg7~Atg8 intermediate. Atg8 is 
transferred from Atg7 to Atg8, producing the thioester-bonded Atg3~Atg8 intermediate. 
Relieved from Atg7, Atg3E123IR protects the Atg3~Atg8 intermediate from wayward 
discharge to errant nucleophiles. The E3 (Atg12–Atg5-Atg16) binds E123IR and further 
activates the Atg3~Atg8 intermediate for nucleophilic attack. Numerous interactions with 
membranes place this complex in proximity to PE for the lipidation reaction.  
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Atg12–Atg5 mediates activation in part by promoting interactions between Atg3 and 
Atg8 in the Atg3~Atg8 intermediate, although details of the interaction remain elusive 
and might be distinct for the autophagy enzymes. 
 
Why might the UBL conjugation pathway in autophagy involve such elaborate 
allosteric control? It seems likely that key features of the ultimate target, and intrinsic 
capabilities of the Atg3~Atg8 intermediate, impose distinctive requirements for 
regulation. First, the substrate PE is among the most abundant core glycerophospholipids. 
Found in several organelles, PE’s widespread accessibility differs from canonical UB and 
UBL substrates, which typically only are licensed for modification after a regulatory 
event such as a post-translational modification directs E3 binding. Second, through its N-
terminal membrane-curvature sensing helix, Atg3 itself can bind the substrate PE (Nath 
et al., 2014). The active site of Atg3~Atg8 may require protection to prevent inopportune 
discharge to PE, and this is best ensured by coming from the intermediate itself. Indeed, 
when conformationally activated by E3-mimicking mutations, Atg3~Atg8 can not only 
catalyze the lipidation reaction and in vivo, but also robustly discharges Atg8 to 
nonspecific nucleophiles even in the absence of E3. Thus, our data present a mechanism 
ensuring that Atg8 discharge is coupled to E3 binding , which in turn establishes 
targeting specificity through several features, including binding to cargo receptors 
(Fracchiolla et al., 2016) , and to membranes (Lystad et al., 2019; Romanov et al., 2012). 
The Atg16 moiety in the autophagy E3 could subsequently engage the lipidated Atg8 to 
serve as a scaffold during autophagosome biogenesis (Kaufmann et al., 2014). 
 
Allosteric E2 activation is emerging as a common property of E3 ligases (Buetow 
and Huang, 2016; Cappadocia and Lima, 2018; Zheng and Shabek, 2017). It is now well-
recognized that many E3 catalytic domains stabilize a “closed” conformation that renders 
E2~UB and E2~UBL intermediates susceptible to nucleophilic attack, while other E3 
domains mediate substrate targeting. Many E2s are further activated allosterically, 
through their backside beta-sheets binding to noncatalytic E3 domains. These effects 
have largely been characterized for indirectly increasing binding to E3 RING domains. 
However, some E3 or E3-associated domains also trigger conformational changes at E2 
active sites. For example, the membrane E3-associated Cue1p binds to Ubc7p’s backside, 
and indirectly modulates the active site, tens of angstroms away (Metzger et al., 2013). 
Irrespective of whether E2 cysteines require protection from errant nucleophilic attack, or 
coordination of catalytic activation with other E3 functions, it seems likely that allosteric 
modulation of E2 active sites serves as a failsafe ensuring UB and UBL discharge at 
appropriate targets. The autophagy E2 Atg3 now serves as an ultimate case, with its brace 
self-imposed until directly lifted by the E3 to drive autophagy. 
 
Apparently, lifting off the E123IR from Atg3 in the Atg3~Atg8 intermediate is 
not sufficient to fully activate Atg8-lipid conjugation, since adding E3 to WT Atg3 
accelerates Atg8 lipidation more robustly than the auto-releasing Atg3 mutants in 
absence of E3. Moreover, our preliminary data from introducing additional E123IR 
peptides into in vitro constituted Atg8 lipidation system shows that E123IR is not 
sufficient to fully block the reaction. Here we suspect that other elements within the Atg3 
FR may also help tuning the interactions between Atg3~Atg8 intermediate and Atg12–
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Atg5-Atg16. Our hypothesis can be tested by other research methods including solving 
the structure of the active conformation of Atg3~Atg8-Atg12–Atg5-Atg16 complex. 
However, since Atg3~Atg8 adopts multiple conformations shifting between active and 
inactive states, obtaining homogeneous in vitro recombinant protein samples of 
Atg3~Atg8-Atg12–Atg5-Atg16 can be exigent. Besides, since Atg3 contains several long 
flexible regions (e.g. FR and partial HR) that couldn’t be removed due to their 
indispensable roles in enzyme function, it will be very challenging crystallizing the full 
complex. It is also potentially taxing to obtain cryo EM structures to display details of all 
the functional parts if they are largely unstructured.  
  
As we discovered in this study, the C-terminus of Atg3 is associated with Atg8 
when Atg3~Atg8 intermediate adopts the closed conformation, and its distinctive 
reversed AIM-like amino acid sequence of Met-Glu-Gly-Trp leads to the speculation that 
such interaction is realized by Atg8-AIM binding. In fact, interactions between Atg8 
family protein and C-terminal LIR/AIM of other autophagic enzymes are not 
unpresented. The C-terminus of the autophay E1 Atg7 docks into the AIM-binding 
groove of its substrate Atg8, though it doesn’t harbor a traditional AIM sequence (Noda 
et al., 2011). In human protein studies, the Phe-Glu-Ile-Leu sequence approaching the 
very end of ATG4 serves as a canonical LIR as binding to GABARAPL1, and was 
proved essential for ATG4’s protease activity (Skytte Rasmussen et al., 2017). 
Intriguingly, such binding event similar to that between Atg8 and Atg3 C-terminus also 
takes place between canonical E2 and UBL. For example, the last few amino acids of 
yeast Cdc34 was proved directly binding to its substrate ubiquitin. Such interaction is 
functionally pronounced for Cdc34’s catalytic activity (Choi et al., 2010). 
 
According to our preliminary result of the Atg8 lipidation assay conducted inn S. 
cerevisiae in vivo cells, not all alanine mutagenesis introduced to the Atg3-binding sites 
in Atg8 showed decreased densities in lipidated Atg8 bands, while some mutants even 
harbor significantly higher lipidation levels. As we speculate, this inconsistency against 
the in vitro results using the same set of mutants (Figure 3-1) could be due to countering 
impacts from Atg4 against Atg3: for some Atg8 mutants, PE conjugation activity is 
impaired by defective Atg3-binding; however Atg4-mediated Atg8 cleavage from 
autophagic membrane is also diminished at the same time. Intriguingly and as expected, 
the Atg3- and Atg4-binding surfaces are largely overlapped on Atg8 if using human LC3-
ATG4B structure for comparison (Satoo et al., 2009). The results bring up a reasonable 
hypothesis that Atg8 binding to Atg3 and Atg4 is mutually exclusive, given Atg4 and 
Atg3 potentially play opposite roles in maintaining the total amount of lipidated Atg8 
during autophagy progression. The unknown molecular requirements determining Atg8’s 
preference between Atg4 and Atg3 indicate that Atg8–PE conjugation, as well as the 
whole autophagy flux, involves more complicated and delicate signaling pathways that 
need to be further studied. 
 
Researchers now have limited knowledge about the membrane binding functions 
within enzymes in Atg8 lipidation cascade. Human protein study has shown that the N-
terminal helix of Atg3 serves as membrane curvature detector which prefers binding to 
higher curvature liposome (Nath et al., 2014). Similar to other canonical E3 ligases that 
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create physical proximity between E2~UBL intermediates and their specific substrates by 
binding to both, Atg12–Atg5-Atg16 also harbors membrane binding affinity in order to 
bring Atg3~Atg8 to substrate PE. According to the study in Saccharomyces Cerevisiae, 
membrane binding is mediated by Atg5, activated by Atg16, but inhibited by Atg12 
(Romanov et al., 2012). Tested with in vitro lipid vesicles, this membrane binding feature 
enables the E3 complex to tether isolated membrane in absence of Atg8, and is also 
essential for autophagosome engulfment more than just for Atg8 lipidation (Romanov et 
al., 2012). However, the Atg5-lipid binding event takes place later than Atg12–Atg5-
Atg16 being located to the pre-autophagosomal structure (PAS) (Romanov et al., 2012), 
which suggests that the membrane system also utilizes other E3 recruiting mechanism 
besides Atg5 interaction. In addition, recent studies reported multiple lipid-recognition 
domains across ATG16L1, including its N-terminal amphipathic helix, the C-terminal 
end, and the coiled-coil domain (Lystad et al., 2019). Notably, ATG16L1 harbors 
intrinsic lipid-binding that is independent from WIPI-mediated recruitment to PAS 
(Lystad et al., 2019). Multiple binding sites within the E2 and E3 complex, especially 
when they do not rely on one another or other lipid-binding machineries, indicates 
sophisticated regulatory mechanism orchestrating Atg8 family protein lipidation. The 
complicated nature of Atg12–Atg5-Atg16 interaction to PAS also hypothesizes that the 
roles of Atg12–Atg5-Atg16 in autophagy may be of greater variety than only to directly 
facilitate Atg8 transfer from Atg3 to PE. 
 
According to current studies, inhibitors for autophagic proteins, especially for 
enzymes in Atg8 family protein lipidation cascade, are not being extensively 
investigated. Potential drug screenings against the lipidation enzymes may provide 
therapeutics to related diseases. Considering this, a great variety of distinctive 
mechanisms in the lipidation machinery can be targeted. Obviously, making protein-
protein interaction inhibitors is a reasonable idea to directly suppress LC3 lipidation 
activity, and to consequentially downregulate the entire autophagy level. Besides, 
cysteine interaction inhibitors could specifically attenuate the nucleophilic attacking 
efficiencies of autophagic E1 or E2, yet not interrupting E2-UBL, E2-substrate and E3-
E2 interactions. Nonetheless, our study also sheds light on the possibility to design Atg3 
allosteric inhibitors, which allows more fine-tuned regulation by arresting Atg8 family 
protein lipidation in inactive states, and avoids disturbing any intrinsic enzyme activities. 
In summary, the dynamic nature of the Atg8 family protein lipidation system has now 
become an opportunity for drug discovery. 
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